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ABSTRACT
Structural Determinants of Murine Leukemia Virus (MLV) Reverse Transcriptase
(RT) Important for Fidelity and Drug-Resistance In Vivo
Elias Konstantine Halvas
Error-prone DNA synthesis by retroviral reverse t anscriptases (RTs) is a major
contributor to variation in retroviral populations generating mutants that exhibit altered
host tropisms, resistance to antiviral drugs, and the ability to escape the host’s immune
system.  To identify structural elements of murine leukemia virus (MLV) RT important
for fidelity and drug-resistance in vivo, we developed a D17-based encapsidating cell line
(ANGIE P) which is designed to express the amp otropic MLV envelope.  ANGIE P cell
line also contains an MLV-based retroviral vector (GA-1), which encodes a wild-type
bacterial b-galactosidase gene (lacZ) and a neomycin phosphotransferase gene.
Transfection of ANGIE P cells with wild type or mutated MLV gag-pol expression
constructs generated GA-1 virus that was able to undergo only one cycle of viral
replication upon infection of D17 cells.  The infected D17 cell clones were characterized
by staining with X-Gal and the frequencies of inactivating mutations in lacZ were
quantified.  Several structural determinants of MLV RT were identified that were
important for fidelity which included position V223 of the YVDD box, several residues
of the dNTP-binding site, as well as residues residing in the RNase H domain of MLV
RT.  A number of these MLV RT mutants resulted in statistically significant decreases in
fidelity (1.2 to 2.8-fold) whereas two mutants showed a statistically significant increase
in fidelity (0.8-fold) relative to wild-type MLV RT.  Furthermore, these amino acid
residues were observed to play critical roles in catalysis and viral replication, which was
exhibited by the reductions in both viral titers as well as RT activities of these mutants.
In addition to identifying structural determinants important for fidelity, we also showed
that the V223 position of MLV RT may not be the only structural determinant important
for resistance to the antiviral nucleoside analog, 2’, 3’-dideoxy-3’-thiacytidine (3TC).
This is in contrast to results observed with human immunodeficiency virus type 1 (HIV-
1) RT.  These results establish a sensitive in vivo assay for identification of structural
determinants important for accuracy of DNA synthesis as well as dug-resistance and
indicate that several structural determinants may have an effect on the in vivo fidelity of
MLV RT.
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CHAPTER 1
Introduction and Review of Literature
2Retroviruses are pseudo-diploid, single-stranded (ss) RNA viruses which replicate
through a double-stranded (ds) DNA intermediate.  This ds DNA eventually becomes
integrated into the genome of their host where it is known as the provirus.  Thus, these
viruses require a life cycle that utilizes a unique viral polymerase (reverse transcriptase)
as well as cellular DNA and RNA polymerases (17, 99). These viruses are members of
the Retroviridae family that exhibits some of the most genetic diversity present in nature,
giving an inherent genetic heterogenecity known as the quasispecies (28).
This genetic heterogenecity arises from an intrinsically high mutation rate and a
large population size (22, 28).  The high error rate is due in large part to the nature of
reverse transcription (RT) during viral replication and recombination.  Heterogenecity
can also arise as a result of the host polymerases’ fidelity, which are also utilized in the
retroviral life cycle.  Regardless of the mechanism, mutations arise that increase the
variability of the population and in turn can increase the fitness of the viral population.
This phenomena of increased fitness is evident in populations of human
immunodeficiency virus type 1 (HIV-1) where mutations arise that can confer drug
resistance to both nucleoside and nonnucleoside analogs (21, 29, 96).  In addition, escape
mutants that evade the immune system can also be selected for through changes in viral
antigen epitopes (69, 79), thus hindering efforts to develop effective vaccines (103).
Thus, the collapse of a host’s immunological response and a failure in the efficacy of
antiviral drugs may accelerate the progression of acquired immunodeficiency syndrome
(AIDS), which results from HIV-1 infections.  Therefore, dissection of the mechanisms
3by which this variation arises may provide us with important insights on how viruses like
HIV-1 evolve.
Genomic structure of retroviruses.  Infections resulting from members of the
Retroviridae family have been identified in a number of vertebrate hosts including,
mammals, fish, birds, reptiles and even insects (17, 55, 81).  The genomes of these
viruses contain two copies of plus-strand RNA ranging between 7-10 kb in length which
are modified in the same manner as eukaryotic mRNAs.  These modifications include, 5¢
capping and 3¢ polyadenylation as well as methylation (12, 17, 51).  The genomes of
these viruses are arranged into three genes with the nomenclature gag, pol and, env (Fig.
1).  The gag gene, encoding several structural proteins forming the core of the virus, is
transcribed and translated as a polyprotein that is cleaved into (MA), capsid (CA) and
nucleocapsid (NC) (17, 46, 78).  The pol gene encodes RT and integrase (IN), two
polypeptides residing in the viral particle core and employed in the early steps of
retroviral replication (1, 17).  In addition, a region of the genome between gag and pol
codes for an aspartic protease (PR) required during the processing of the polypeptide
precursors into their respective subdomains (17, 68).  Depending on the retroviral
species, PR can be expressed as a part of gag as bserved in avian leukemia virus (ALV)
or as a part of pol, as seen in murine leukemia virus (MLV) (17).  Finally, the env gene
codes for a glycosylated polyprotein translated from spliced subgenomic RNA and
processed by cellular proteases.  The resultant products of the processed polypeptide are
designated as the surface (SU) and the transmembrane (TM) subunits of the viral surface
glycoprotein that protrudes from the enveloped surface of the virus.  This protein
4complex is utilized during the attachment and entry of the virus into the target cell (17,
48).
The retroviral RNA genome also possesses non-coding sequences functioning as
cis-acting elements with vital roles during reverse transcription, integration, transcription,
splicing and packaging (Fig. 1).  At the 5¢ and 3¢ ends of the viral RNA are identical
sequences termed R (repeated sequences) important during the obligatory jumps of
reverse transcription (17).  Sequences directly down stream of the 5¢ R include the unique
5¢ sequence (U5), which comprise of elements critical for termination of transcription
(Poly A) and attachment during integration (att).  In addition to U5, the primer binding
site (PBS), the site where reverse transcription initiates, is also present directly down
stream of 5’ R (16, 17, 37).  Additional cis-acting sequences at the 5¢ end of the retroviral
genome include the splice donor site utilized in the generation of subgenomic mRNA
followed by the packaging signal designated as either Y or E (17).  The cis-acting
elements of the unique 3¢ r gion (U3) of the retroviral genome include the polypurine
tract (PPT), the second att site and sequences possessing transcriptional enhancer activity
(17, 37, 59).
Retroviral replication.  A complex set of events transpires in the movement of
genetic information from RNA to DNA and back to RNA.  This is characterized as the
retroviral life cycle (Fig. 2), which begins with virion attachment to the cell through
protein-protein interactions between viral surface glycoprotein and cellular receptor (17).
Attachment of the viral particle to the cell surface receptor promotes fusion of both
envelopes leading to internalization of the viral particle and release of the nucleocapsid
complex into the cytoplasm.  Reverse transcription proceeds with conversion of the
5single-stranded RNA genome into double-stranded DNA and eventually, the integration
of this DNA into the host’s genome by integrase.  This provirus in turn is transcribed,
processed, and translated by host machinery including RNA polymerase II, spliceosomes,
and ribosomes respectively.  These translated proteins are targeted to the cellular
membrane, assemble into viral particles packaging two full-length transcripts of the viral
genome and finally bud from the cell.  During budding, processing of the polypeptides by
viral protease occurs which leads to the generation of mature virions.  This newly
released particle is prepared for another round of viral infection (17).
Reverse transcription.   An important event in the retroviral life cycle is the
process known as reverse transcription converting single-stranded RNA into double-
stranded DNA (Fig. 3) (17, 37).  This transformation takes place in two distinct stages
and two sets of templates are employed.  In the first stage, reverse transcription initiates
at the PBS using a virus-specific cellular tRNA as a primer and proceeds to the 5¢ end of
the RNA molecule copying the U5 and 5¢ R.  This short DNA product known as minus-
strand strong stop DNA, is transferred to the 3¢ end of the genome, during the first
obligatory jump.  This jump is thought to be facilitated by the RNase H domain of RT
that degrades the RNA component of the RNA-DNA duplex as well as by base pairing
between both the 5¢ (minus-strong stop DNA) and 3¢  (genome) R regions.  Reverse
transcription continues, moving from the 3¢ end of the RNA genome towards the PBS and
as polymerization occurs, RT-associated RNase H degrades the RNA template.
During the second stage of reverse transcription (44), as minus-strand DNA
synthesis proceeds towards the PBS, the RNase H domain of RT makes a specific
cleavage in the RNA genome at the PPT (32, 83).  At this point, the minus strand can be
6used as a template in order to synthesize plus-strand strong stop DNA that copies the U3
R U5 (LTR) sequence as well as a region of the tRNA.  The plus-strand strong stop DNA
is transferred to the 5¢ end of the minus strand and hybridizes to a complementary PBS on
the minus-strand DNA.  Once this has occurred, DNA synthesis proceeds in both
directions producing the dsDNA intermediate with LTRs at both ends.  RNase H removes
the tRNA primer and the viral integrase inserts the dsDNA into the host’s chromosome.
Reverse transcriptase.  The process of reverse transcription relies on the viral
enzyme RT, an RNA- and DNA-dependent DNA polymerase with associated RNase H
activity.  Due to the central role RT plays in the retroviral life cycle, many of its amino
acid motifs are strictly conserved, even among divergent retroviral species (80).  This
observation can be expanded to the RTs of retroelements as well as to the structurally
similar cellular enzyme, telomerase (72, 80).  Despite the low primary sequence
homology between these polymerases, sequences such as the dNTP binding pocket
including the Thr-Val-Leu-Asp (TVLD) sequence, the Leu-Pro-Gln-Gly (LPQG) motif,
and the Tyr-X-Asp-Asp (YXDD) box are highly conserved among RTs, therefore hinting
at critical roles that these amino acids partake in proper polymerase function.  Previous
studies analyzing solvent accessibility have provided data placing the residues of these
motifs in close proximity to the active site of RT (96).
Crystal structure of HIV-1 RT.  The crystal structure of HIV-1 RT complexed
with a non-nucleoside inhibitor at a resolution of 3.5 Angstroms, shows that the enzyme
is a highly elongated, asymmetric heterodimer composed of two polypeptides, 66 and
51kD, respectively.  A simplistic three-dimensional view of HIV-1 RT has been
compared to a right hand (Fig. 4 and 5A) (47, 49, 57, 96).  The p66 subunit can be
7separated into five domains that includes the fingers, thumb, palm, connection and the
RNase H domains (20, 49, 57).  The fingers, palm and connection domains are composed
of several mixed b-sheets and a-helices whereas the thumb domain is characterized as a 4
a-helix bundle.  The p51 subunit is a truncated version of p66 lacking the RNase H
domain.  The overall tertiary structure of the p51 subunit domains is similar to the p66
subunit, yet the spatial arrangements of these domains differ between the two subunits
(49, 57).  Both subunits contain a polymerase active site found in the palm domain, yet
only the one present in p66 is active.  Finally, a nucleic acid binding cleft runs between
the polymerase active site and the RNase H domain (57).
The crystal structures of several ternary complexes of HIV-1 RT have been
elucidated providing structural information on how the protein may function and interact
with its substrates (Fig. 5A and B) (47, 49).  In one study, HIV-1 RT has been
crystallized with dsDNA template-primer at a resolution of 3.0 Angstroms (49).  It was
observed in this model that several interactions can occur between the fingers, thumb and
palm domains of the protein with the sugar-phosphate backbone of the nucleic acid.
This involves both the aH and aI helices of the thumb domain that bind to the primer and
template backbones, respectively.  Further interactions between RT and primer may
involve the b12-13 hairpin (primer grip) and regions including portions of the fingers,
thumb and palm (template grip) may position the template.  In addition, the dsDNA was
shown to adopt both A and B forms that were separated by a 40-450 bend.  The
significance of these adopted forms of DNA and RNA may influence cleavage events by
the RNase H domain (3).
8Recently, a ternary complex of HIV-1 RT with template-primer and
deoxythymidine triphosphate (dTTP) was determined, implicating several residues in the
direct binding of the incoming deoxyribonucleotide triphosphate (dNTP) (47). These
residues include K65, R72, D113, A114, Y115, and Q151, located in the dNTP binding
pocket of HIV-1 RT (Fig. 5B).  The side-chains of both K65 and R72 as well as the main-
chain amides of D113 and A114 interact with the triphosphate moiety of incoming dTTP
through hydrogen bonding.  In addition, the R72 residue interacts with the base of the
incoming substrate. Mutational analysis of these positions in HIV-1 RT has revealed
information implicating these residues with positional effects on the template-primer
complex, conformational changes of RT as well as pyrophosphate exchange (47, 61, 89,
96).  Residues Y115 and Q151 side-chains were also shown to interact with the base of
the dTTP substrate.   The aromatic ring of the Y115 is in close proximity to the ribose
moiety and may play a role in the selectivity of dNTPs versus ribonucleotides (rNTPs).
Comparison of these crystal structures and a closer inspection of the active site of
HIV-1 RT places the terminal 3¢ hydroxyl group of the primer in close proximity to
residues of the YMDD box (47, 49, 57). Residues of this particular motif, specifically the
Tyr and Met (Y183 and M184), have been implicated with catalytic function, infectivity
potential, positioning of template-primer complex, processivity, and fidelity (5, 13, 96,
106).  In addition, the two Asp residues (D185 and 186) in accordance with Asp (D110)
of the dNTP binding pocket are believed to coordinate magnesium (Mg2+) important in
the metal-mediated nucleotidyltransferase reaction (61, 62).
Several crystal structures of unliganded HIV-1 RT have been resolved revealing
difference between both unliganded and complexed enzyme (30, 45, 47, 49, 57).  Both
9subtle and major structural changes have been observed when comparing these structures.
One of the more profound changes involves the thumb, which is characterized by a 300
displacement when comparing the structures of HIV-1 RT in the absence or presence of
DNA.  Interestingly, the geometry of the active site seems to be unchanged in the
presence or absence of this substrate.
Crystal structure of MLV RT.  The crystal structure of a catalytically active
MLV RT fragment containing the fingers and palm domains has been determined at a
resolution of 1.8 Angstroms.  In addition, the crystal structure of this catalytic fragment
complexed with a Mn2+ cation was also determined at a resolution of 2.6 Angstroms (Fig.
6) (36).  The structure reveals that the fingers and palm domains of this crystallized
fragment are composed of a helices and b sheets.  In a junction between these fingers and
palm domains resides the b10-b11 turn that includes the highly conserved YVDD box.
The amino acids of this motif and those of the putative dNTP-binding site are believed to
create the active site of the polymerase. This includes the catalytic triad (D150, D224,
and D225) that has been observed to coordinate Mn2+ a d which may play a critical role
in catalysis.
Sequence alignments of MLV and HIV-1 RTs reveal that both polymerases share
many of the highly conserved motifs (TVLD, LPQG and YXDD boxes) and possess
similar tertiary structures despite only a 25% amino acid identity (36, 80).  In addition,
this sequence alignment suggests that residues K103, R110, D153, A154, F155, and
Q190 in MLV RT are equivalent to residues K65, R72, D113, A114, Y115, and Q151 in
HIV-1 RT, respectively as described in Chapter 3.  Furthermore, the HIV-1 RT
equivalents have been observed to directly contact the incoming dTTP substrate (47).
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The involvement of these MLV RT residues (K103, R110, D153, A154, F155, and Q190)
in binding of incoming dNTP is supported by previous studies implicating residues like
K103 and F155 of MLV RT with dNTP binding and selectivity, respectively (6, 34, 36).
In contrast, MLV RT possesses a number of additional features absent from HIV-1 RT
including 40 amino acids at the N-terminal end as well as several additional b sheets and
a helices.  Finally, the crystallized fragment of MLV RT is accompanied by subtle
changes in both the fingers and palm domains when compared to HIV-1 RT (36, 45).
Fidelity associated with reverse transcriptase.  An important property of
polymerases is fidelity, defined as the accuracy the enzyme displays in copying a
template.  The fidelity of a polymerase can be measured as the mutation rate, the rate at
which mutations are introduced during synthesis of nascent DNA.  Fidelity of
polymerases, including RTs, can be measured in vitro or in vivo employing the use of
either reversion or forward mutation assays.
The reversion assay, characterized by an inactivated reporter gene containing a
substitution, measures the rate at which a functional gene is reconstituted.  The rate of
this genes reconstitution is equal to the mutation rate (23, 24).  Limitations associated
with this assay typically involve a small number of mutational targets providing
measurements that are not indicative of the average mutation rate, since mutations can
occur in a sequence dependent manner.  In contrast, the forward mutation assay involves
the use of a functional reporter gene and measures the rate at which this gene is
inactivated by substitutions introduced during DNA synthesis.  The frequency with which
this inactivation occurs is set to equal the mutation rate (63, 64, 74-76).  This type of
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assay ordinarily allows for a larger number of mutational targets providing improved
measurements of an average mutation rate in comparison to the reversion assay.
Since the retroviral life cycle employs the use of cellular DNA and RNA
polymerases as well as RT, mutations contributing to genetic diversity can be introduced
at several points of this life cycle from any one of these enzymes.  Mutation rates of
cellular DNA polymerases have been estimated to be on the order of 10-9
substitutions/bp/cycle of replication, an impressive feat involving highly processive DNA
synthesis and the utilization of proof-reading mechanisms (58).  Due to the highly
accurate DNA synthesis exhibited by these polymerases, the effects on the overall
mutation rate associated with retroviral replication is probably negligible.  The mutation
rate of RNA polymerase has not been determined and may contribute to the overall
mutation rate, however, proofreading activity has been recently observed with this
protein (101).  Therefore, with the increased fidelity of this enzyme, its contribution to
the overall mutation rate is likely minimal.  It has been hypothesized that the major
contributor of mutations introduced in the retroviral life cycle may be attributed to RT as
a result of its less processive nature and the absence of proofreading activity (7, 100).
Mutation rates of various RTs have been measured both in vivo and in vitro (9, 10, 77).
In vivo mutation rates of several RTs where shown to range between 3.4 × 10-5 and 4.8
×10-6 mutations/bp/replication cycle (63, 64, 74-76), approximately 1,000 to 10,000-fold
more error-prone than the cellular DNA polymerases.
A comparison of mutation rates obtained by both in vitro and in vivo assays for
HIV-1 RT reveals measurements varying by approximately 20-fold (9, 63).  These
discrepancies, at least in the case of the cell-free in vitro assays utilizing purified RT,
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dNTPs and exogenous template-primer complexes, may be attributed to several factors
including, both Mg2+ and dNTPs concentrations as well as pH (14, 27, 65, 104).  In
addition, damage of polymerases during the purification process can also alter the fidelity
of these enzymes (14, 58, 84).  Therefore, in light of these differences, there is a need to
analyze the fidelity of RTs in vivo, within the context of a replicating reverse
transcriptase complex.  This may provide a more appropriate assessment of how RT
fidelity is manifested in a physiological setting.
Structural determinants of RT important for fidelity.  As illustrated
previously (Fig. 4, 5A, 5B, and 6), the tertiary structure of various RTs resembles a right
hand with fingers, palm and thumb domains (36, 47, 49, 57).  Interactions between the
RT (fingers, thumb, and palm domains) and substrates (template-primer and dNTP), may
result in correct positioning of these substrates in a fashion that promotes polymerization.
Collectively, substitutions in any of these domains may exert effects on the overall
fidelity of the polymerase.  In support of this hypothesis, several amino acids and/ or
structural motifs in various RTs have been observed in vitro to be important for fidelity
(5, 8, 11, 25, 26, 43, 52, 56, 66, 67, 73, 86, 97, 107).  For example, the Y183F and
M184V mutations in the YMDD motif of HIV-1 RT displayed enhanced fidelity
compared to wild type (5, 25, 73, 105).  Similar results were observed with the Y222F
mutant of MLV RT (52).  Mutations L74V, D76V, E89G, and F160W introduced in the
fingers and palm domains of HIV-1 RT also were associated with increased fidelities (25,
42, 43, 56, 87).  This was also evident in HIV-2 RT, at least for the L74V and E89G
mutants (97).  Finally, mutations introduced in the primer-grip were associated with
significant increases in fidelity in vitro (107).  In addition to increased fidelities, mutants
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like K65R and Q151M exhibited reductions in sensitivity to a number of
dideoxynucleoside analogs (38, 85).  Conversely, increases either in frameshifts,
misincorporations, or mispair extensions resulted when substitutions were introduced
either at residue Y115 (palm) or the a H helix (thumb) in HIV-1 RT (8, 11, 66, 67).
Although, evidence has been compiled for determinants important for fidelity in vitro,
amino acids and motifs responsible for fidelity in vivo are currently unknown.
Fidelity of reverse transcriptase and drug-resistance.  Low RT fidelity leads to
extensive genetic heterogeneity and drug-resistant viruses that arise impede efforts to
combat retroviral infections.  Various inhibitors have been designed targeting several
different steps in the retroviral life cycle.  These inhibitors fall into three classes; those
that target RT, PR or binding/fusion interactions between virus and host (17). In the case
of HIV-1 infections, at least 14 antiretroviral drugs directed against RT and PR are being
utilized today in a clinical setting to hinder the spread of the virus and slow the
progression to AIDS (18, 98).  RT inhibitors are categorized as nucleoside, non-
nucleoside, or pyrophosphate analogs (17, 96).  The nucleoside analogs were among the
first exploited RT inhibitors observed to inhibit reverse transcription (4, 17).  Several
examples of nucleoside analogs include 2¢,3¢-dideoxy-3¢-thiacytidine (3TC), 3¢-azido-3¢-
deoxythymidine (AZT), 2¢,3¢-dideoxycytidine (ddC), 2¢,3¢-dideoxyinosine (ddI), and
2¢,3¢-didehydro-3¢ deoxythimidine (d4T).  Compelling data from various studies suggest
that combinations of these RT inhibitors with other antiretroviral inhibitors can prolong
life expectancies and delay the progression of AIDS (19, 33, 40, 41, 70, 71).  However,
prolonged treatment with antiviral drugs eventually results in the generation of drug-
resistant mutants in both patients and tissue culture-based systems (35, 39, 53, 60, 90,
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102).  For example, within the YMDD motif of HIV-1 RT, the M184V, M184I, or the
M184T mutations are associated with 3TC resistance (35, 90, 102).  In addition, similar
mutations are observed in the homologous amino acid positions of the simian
immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), and hepatitis B
virus (HBV), suggesting a common mechanism through which the enzyme acquires
mutations that confer resistance (2, 15, 93).  Contrary to the single amino acid
substitution associated with 3TC resistance, AZT resistance requires the introduction of
several mutations in and around the active site of HIV-1 RT (53, 60).  his resistant
phenotype is characterized by the M41L, D67N, K70R, T215Y/F, and K219Q mutations.
Furthermore, a number of mutations in HIV-1 RT result in cross-resistance to several
nucleoside analogs simultaneously (35, 39, 54, 82, 91, 92, 94). For instance, both the
M184V and L74V mutations have been shown to be cross-resistant to ddC and ddI (35,
39, 94).  Also, the K65R, E89G, and G333E mutations all exhibit a resistance to 3TC in
addition to ddC, phosphonoformic acid, or AZT, respectively (39, 54, 82).  Finally, the
multi-drug resistant mutation Q151M confers resistance to AZT, ddI or ddC (91, 92).
Elucidation of the ternary complex of HIV-1 RT with template-primer and dTTP
substrates reveals that not all mutations associated with drug resistance are located within
the active site of the polymerase (47).  Interestingly, drug-resistant mutations to
nucleoside analogs can fall into two categories.  The first group includes mutations that
reside in and around the dNTP binding site and these changes alone are sufficient to
display this drug-resistant phenotype through mechanisms involving steric hinderance or
alterations in the nature of drug binding (31, 47, 88).  This includes a number of positions
in HIV-1 RT such as R72, L74, Q151, and M184 that directly contact either the template-
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primer complex or the incoming dNTP.  For instance, L74 holds the templating base,
M184 interacts with the sugar-moiety (3¢ nucleotide in primer), where as R72 and Q151
interact with the base of the incoming dNTP.  Therefore, it is possible that substitutions at
any of these positions can cause changes that eventually shift positioning of the incoming
dNTP and alter catalysis or the nature of substrate binding.  In contrast to mutations
situated in the active site, the second set involves modifications located away from this
pocket.  These mutations may reinforce the changes associated with the drug-resistant
mutations of the active site and realign critical residues important for proper function of
the enzyme (47).
A comparative analysis of HIV-1 and MLV RTs demonstrates a number of
similarities at both their primary and tertiary levels, despite only an ~25% sequence
homology (36, 57, 80).  In addition, the in vivo mutation rates of these two viruses are
within 2-fold (77).  Furthermore, MLV RT exhibits a drug sensitivity profile similar to
HIV-1 RT (50, 95).  This is characterized by sensitivities to several nucleoside analogs
such as ddI, ddC, d4T, and AZT.  Because of these similarities shared between the two
polymerases, an MLV-based system serves as an ideal model for HIV-1, enabling us to
gain insight into common mechanisms associated with fidelity and the development of
drug-resistance.  Similarities as well as differences between the RTs may also provide
insights into retroviral evolution.
Overview of thesis.  The fidelity of RT may be the major contributor of variation
in retroviral populations, increasing the genetic diversity of the virus and eventually
thwarting drug therapy.  In order to understand the underlining mechanism by which
fidelity is determined, it is critical to identify structural determinants of RTs that are
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important for fidelity in vivo.  In Chapter 2, the development of an in vivo assay to
identify structural determinants in MLV RT important for fidelity is discussed.  Initially,
I developed a rapid assay based on the ANGIE P encapsidating cell line that is sensitive
enough to detect small but statistically significant differences in fidelity between mutants
and wild type RT.  Furthermore, I prove that the V223 position of MLV RT is important
for fidelity in vivo.  In Chapter 3, the effects of substitutions introduced at residues
constituting the dNTP binding site of MLV RT are discussed in correlation to fidelity.  I
demonstrate, through extensive mutational analysis, that residues in MLV RT
hypothesized to come in direct contact with the dNTP substrate are critical for proper
polymerase function and viral replication.  In addition, I show that several substitutions at
these positions exhibit changes in fidelity and reveal that several residues that do not
contact the dNTP can also have profound effects on fidelity in comparison to wild type
RT.  In Chapter 4, the resistance of both wild type and mutant MLV RTs to the
nucleoside analog 3TC are discussed.  I show that several V223 mutants of MLV RT as
well as the wild type are all resistant to 3TC.  Finally, in Chapter 5, I discuss evolution of
retroviruses and explain the impending implications of my studies.
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FIG. 1.  Retroviral genomic structure of MLV.  Both RNA (top) and DNA (bottom)
forms contain the genes gag, pol, and env.  The gag gene codes for structural proteins
such as matrix, capsid, and nucleocapsid, where as pol codes for proteins utilized during
replication such as reverse transcriptase and integrase.  The env gene codes for the
envelope glycoproteins that the virus utilizes during entry into host.  Between gag and
pol is pro, which codes for the viral protease important during assembly and maturation
of virions.  In addition to the coding regions, both the RNA and DNA genomes possess a
number of cis-acting elements designated as the primer binding site (PBS), the packaging
signal (Y), and the polypurine tract (PPT).  The Viral RNA possesses unique 5´ and 3´
sequences designated as U5 and U3 as well as an inverted repeats termed R.  The unique
sequences are duplicated in the DNA form of the retroviral genome and designated as the
long terminal repeat (LTR).
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FIG. 2.  The retroviral lifecycle.  Viral particle binds to cellular receptor, is internalized,
and particle is uncoated.  The RNA genome is reverse transcribed into dsDNA, which
translocates to the nucleus, it integrates into host genome, and the host’s RNA
polymerase transcribes the provirus into mRNA.  Full-length or spliced mRNA exported
to the cytoplasm can be translated into protein or packaged into assembling viral
particles.  Assembled particles bud from the host and can repeat cycle.
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FIG. 3.  Reverse transcription.  Thin lines represent viral RNA showing primer binding
site (PBS), polypurine tract (PPT), unique 5´ and 3´ sequences (U5 and U3), as well as
the inverted repeat (R).  Thick lines represent DNA and dotted lines RNA degradation by
the RNase H domain.  The crooked line represents the tRNA primer.
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FIG. 4.  Crystal Structure of HIV-1 Reverse Transcriptase Heterodimer
p66 Subunit
p51 Subunit
Kohlstaedt et al, 1992
Thumb
Connection
RNase H
Fingers
24
FIG. 5.  HIV-RT complexed with bound ligands.  (A) Heterodimer of HIV-1 RT
complexed with template-primer complex [Jacobo-Molina, et al 1994].  The structure
contains both the p66 and p51 subunits of HIV-1 RT with a bound DNA substrate.  (B)
The dNTP-binding site of HIV-1 RT [Huang, et al 1998].  The incoming dNTP is
characterized as box (B = base), pentagon (R = ribose sugar), and three diamonds (P =
phosphates).  The residue of HIV-1 RT shown to directly contact the incoming dNTP
include the side chains of K65, R72, Y115, and Q151 as well as the main chain (mc) of
D113 and A114).  Contacts between residues and dNTP substrate are shown as dotted
lines whereas the magnesium atom at site B is designated as Mg.
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Figure 5A. HIV-1RT complexed  with DNA
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FIG. 6.  The crystal structure of a catalytically active fragment of MLV RT [Georgiadis,
et al 1995].  The structure includes the fingers and palm domains of MLV RT.  The
residues hypothesized to contact the incoming dNTP substrate are highlighted in black,
which includes K103, R110, D153, A154, F155, and Q190.  The location of both the
YVDD box and the primer grip are also highlighted.
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ABSTRACT
Error-prone DNA synthesis by retroviral reverse transcriptases (RTs) is a
major contributor to variation in retroviral populations.  Structural features of
retroviral RTs that are important for accuracy of DNA synthesis in vivo are
currently unknown.  To identify structural elements of murine leukemia virus
(MLV) RT important for fidelity in vivo, we developed a D17-based
encapsidating cell line (ANGIE P) which is designed to express the amphotropic
MLV envelope.  ANGIE P also contains an MLV-based retroviral vector (GA-1),
which encodes a wildtype bacterial b-galactosidase gene (lacZ) and a neomycin
phosphotransferase gene.  Transfection of ANGIE P cells with wildtype or
mutated MLV gag-pol expression constructs generated GA-1 virus that was able
to undergo only one cycle of viral replication upon infection of D17 cells.  The
infected D17 cell clones were characterized by staining with X-Gal and the
frequencies of inactivating mutations in lacZ were quantified. Three mutations
in the YVDD motif (V223M, V223S, and V223A) and two mutations in the
RNase H domain (S526A and R657S) exhibited 1.2- to 2.3-fold higher
frequencies of lacZ inactivation in comparison to the wildtype MLV RT (P <
0.005).  Two mutations (V223I and Y598V) did not affect the frequency of lacZ
inactivation.  These results establish a sensitive in vivo assay for identification of
structural determinants important for accuracy of DNA synthesis and indicate
that several structural determinants may have an effect on the in vivo fidelity of
MLV RT.
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INTRODUCTION
High mutation rates exhibited by retroviruses generate extensive genetic variation
and confer high evolutionary potential in retroviral populations (14, 42, 43, 52-54, 62).
Variation in human immunodeficiency virus type 1 (HIV-1) populations may in turn affect
the fitness of the species.  For example, genetic variation in HIV-1 populations has
resulted in the selection of mutations that confer resistance to at least 11 antiretroviral
drugs approved for clinical use and selection of escape mutants that evade the host
immune response (15, 46).  Genetic variation has also thwarted efforts to develop
effective vaccines against HIV-1(64).
An important mechanism of generating variation in retroviral populations is the
low fidelity of reverse transcriptase (RT) (42, 43, 52-54).  Mutation rates of RTs can be
measured in vitro or in vivo by employing the use of various assays (5, 42, 43, 53-55).
The measurements of fidelity are often altered by the in vitro assay conditions (18, 39, 44).
Previously, the in vitro mutation rate of HIV-1 was estimated to be approximately 20-fold
higher than the in vivo mutation rate (4, 42).  In vivo forward mutation assays for various
RTs have been determined and range from 1.2 x 10-5 to 4.8 x 10-6 mutations/bp/replication
cycle (42, 43, 52-54).
Amino acid positions and motifs in RT that may be important for the in vivo
fidelity of RT are currently unknown.  However, several studies have identified potential
structural determinants that are important for the in vitro fidelity of RT (1-3, 19, 25-27,
35, 37, 45, 50, 51, 56, 57, 60, 66).  The YXDD motif is highly conserved in RTs and
mutations in the motif are associated with decreases in enzymatic activity and viral
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infectivity, changes in the positioning of the primer in the template-primer complex, and
resistance to nucleoside analogs (10, 12, 15, 59, 67).  In addition, mutations at the
methionine of the HIV-1 YMDD motif have been associated with alterations in the in vitro
fidelity of RT (1, 2, 19, 25-27, 50, 51, 66). Mutation of the HIV-1 YMDD motif to
YVDD (M184V) is associated with high level resistance to the antiretroviral drug (-) 2’,
3’ dideoxy-3’-thiacytidine (3TC) (9, 20, 63).  Several studies have observed large
increases (up to 45-fold) in the in vitro fidelity of HIV-1 RT containing the M184V
mutation (50, 51, 66).  However, another in vitro study using a forward mutation assay
has indicated that the YVDD mutant of HIV-1 RT exhibits less than a 2-fold decrease in
the mutation rate (19).
The amino acids involved in binding to the substrate dNTP may also constitute a
fidelity determinant of RT (26, 29).  Recently, the crystal structure of HIV-1 RT
complexed with the template-primer and the dTTP substrate shows six amino acids that
contact the substrate dTTP (29).  Mutations at three of the positions were associated with
alterations in the in vitro fidelity of RT (26, 45).  Another motif, the aH helix of the HIV-
1 RT thumb domain, binds to the minor groove of the template-primer complex and is
associated with alterations in the processivity and fidelity of RT (3, 6, 30).  Mutational
analysis of the aH helix of HIV-1 RT was associated with lower fidelity in vitro, either
through an increase in the rate of RT dissociation from the template DNA or through an
increase in strand slippage resulting in lower frameshift fidelity (6).  Final y, the RNase H
domain may influence the rate of RT processivity and template switching, which may
result in an increase in the rate of deletions, deletions with insertions, and duplications (21,
24, 33, 41).
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The differences in the fidelities of HIV-1 RT mutants in different in vitro assays
demonstrate a need for analyzing the fidelity of RTs during the course of in vivo retroviral
replication.  Structural similarities between MLV and HIV-1 RTs suggests that
understanding the structural determinants of MLV RT important for fidelity may provide
insights into the fidelity of HIV-1 RT (22, 38).  In addition, a greater understanding of the
mechanisms of MLV RT fidelity may lead to the development of improved MLV-based
vectors and packaging cell lines for gene therapy.  In this study, we have developed an in
vivo assay for rapid measurement of the fidelity of wild type or mutated MLV RTs.  This
assay provides a useful tool to identify structural determinants of MLV RT important for
accuracy of DNA synthesis and to determine the extent to which they influence fidelity in
vivo.
MATERIALS AND METHODS
Plasmids and retroviral vector.  The construction of MLV-based retroviral
vector GA-1 was previously described (34).  The plasmids pLGPS and pAMS, which
expressed the MLV gag and pol genes from a truncated MLV LTR promoter or
expressed a replication competent MLV, respectively, were a kind gift from A. D. Miller
(47, 48).  The plasmid pSV-A-MLV-env, which expressed the amphotropic MLV
envelope gene from the LTR promoter and SV40 enhancer, was obtained from the AIDS
Research and Reference Reagents Program (40).  The plasmid pBSpac encoded the
puromycin N-acetyl transferase gene and conferred resistance to puromycin (65).  The
plasmid pSVa3.6 encodes the a subunit of murine Na+, K+-ATPase gene and confers
resistance to ouabain (36).
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Generation of MLV RT mutants.  Site-directed mutagenesis of pLGPS was
performed by utilizing the Morph Kit (5’-3’, Inc.) or the Chameleon kit (Stratagene).  A
detailed description of the mutagenic oligonucleotides and the strategies used to identify
mutants is available upon request.  Briefly, most of the mutagenic oligonucleotides were
designed to introduce additional silent mutations and generate new restriction sites.
Restriction digestion analysis was performed to identify plasmids containing mutations.
DNA fragments ranging in size from 479-1230 bp from the plasmids containing mutations
were subcloned into pLGPS.  The inserted fragments were analyzed by DNA sequencing
to verify the presence of the desired mutation and the absence of any undesired mutations
(ALF Automated Sequencer, Pharmacia).
Cells, transfections, and infections.  D17 dog osteosarcoma cells were
transfected, infected with MLV, and selected for resistance to ouabain or G418 (a
neomycin analog) as previously described (33, 34).  The D17 cells were selected for
resistance to puromycin (final concentration, 3.2 × 10-6 M). The D17-derived ANGIE P
cells were maintained, transfected, and selected for resistance to ouabain in a similar
manner.
Protocol for determination of in vivo fidelity.  The ANGIE P cells were plated
at a density of 2 ´ 105 cells per 60-mm diameter dish, and 24 h later cotransfected with
wildtype or mutated pLGPS and pSVa3.6.  The transfected cells were selected for
resistance to ouabain and the resistant colonies were pooled and expanded.  The ouabain-
resistant cells were plated at a density of 5 ´ 106 cells per 100-mm diameter dish; 48 h
later the culture media containing GA-1 virus was harvested and used to infect D17 target
cells.  The infected D17 cells that were resistant to G418 were stained with X-Gal and the
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frequency of lacZ inactivation was determined by quantification of lacZ expressing blue
colonies and non-expressing white colonies.
Virus preparation and reverse transcriptase assay.  To isolate and concentrate
virus, helper cells containing different constructs were plated out at 5 ´ 106 cells per 100-
mm dish.  Viruses were collected 2 days later and centrifuged at 25,000 rpm for 90 min in
an SW41 rotor (Beckman) at 40C. Viral pellets were resuspended in culture media or
phosphate buffered saline (PBS) and virus was stored at –800C.  Concentrated virus was
thawed on ice and the reverse transcriptase activities were determined by modification of
previously described method (23).  Briefly, 50 mg/ml of (20-mer) oligo T (Integrated DNA
Technologies), 100 mg/ml poly A (Pharmacia), and 10 mCi 3H dTTP (specific activity of
72 Ci/mMol, ICN) were used in the reactions.  The reaction mixtures were precipitated
with 10% trichloroacetic acid (Sigma), filtered through 0.45 mm Metricel membranes
(Gelman Sciences, Inc.), and the incorporated 3H dTTP was determined using a
scintillation counter.
Western blot analysis.  Western blots used to quantitate the amount of protein
for the RT assay were performed using standard procedures (58).  Briefly, viral proteins
were resolved on a 15% SDS-polyacrylamide gel, transferred to membranes (Gelman
Sciences, Inc.), and incubated with a 1:10 dilution of a rat anti-MLV capsid monoclonal
antibody (13).  The membranes were further incubated with anti-rat IgG antibody
conjugated with horseradish peroxidase (Southern Biotechnology Associates, Inc.) at a
1:10,000 dilution. The MLV capsid was detected using an ECL kit TM (Amersham
Pharmacia Biotech) and quantitative autoradiography using a densitometric program
(Optimas).
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PCR analysis and characterization of proviral DNA.  A total of 161 individual
G418-resistant clones infected with GA-1 were isolated and grown in duplicate 24-well
tissue culture dishes.  Mutant colonies were identified by staining one 24 mm-well dish
with X-Gal.  Eleven mutant cell clones and six wildtype cell clones were expanded on 60-
mm diameter dishes.  The expanded cells were lysed and proviral DNAs amplified by two
rounds of PCR (28, 58).
Three pairs of forward and reverse primers that annealed to six different regions in
GA-1 were employed to amplify three overlapping fragments of lacZ.  DNAs obtained
from the first round of PCR were further amplified by a second round of PCR utilizing
nested primer sets (58).  PCR products (1216-1326 bp) were further analyzed for smaller
deletions or insertions by digestions with various restriction enzymes (BstUI, HaeIII,
HhaI, DpnII, HpaII, and NlaIII) and electrophoresis using 7% polyacrylamide g ls or 3%
MetaPhor gels (MetaPhor agarose, FMC).
Southern analysis of proviral DNA.  Genomic DNA was isolated from the
ANGIE P ecapsidating cell line and the proviral structure was analyzed by Southern blot
hybridization using standard procedures (16, 58).  A 1.2-kb fragment of WH390
containing IRES-neo was used to generate a probe (specific activity > 109 cpm/mg) as
previously described (16).  Quantitation of bands was accomplished with the ImageQuant
program (Molecular Dynamics).
RESULTS
Construction of ANGIE P encapsidating cell line.  The MLV-based retroviral
vector pGA-1 and the MLV envelope expression construct pSV-A-MLV-env (Fig. 1A)
were introduced into D17 cells to generate the ANGIE P encapsidating cell line (Fig. 1B).
54
The vector GA-1 possesses all cis-acting elements needed for viral replication, which
include the long terminal repeats (LTRs), the MLV encapsidation signal (Y), primer
binding site (PBS), and the polypurine tract (PPT).  In addition, the vector expresses the
bacterial b-galactosidase gene (lacZ) and the neomycin phosphotransferase gene (neo)
from a single RNA transcript initiating in the 5’ LTR.  An internal ribosomal entry site
(IRES) of encephalomyocarditis virus is used to express neo (31).  The construct pSV-A-
MLV-env expresses the amphotropic MLV envelope using a modified MLV LTR
promoter.
To construct the ANGIE P encapsidating cell line, pGA-1 was first transfected into
the MLV-based packaging cell line PG13 and G418 resistant cells were selected.  Virus
harvested from the pool of transfected PG13 cells was used to infect D17 cells.  After
selection for G418 resistance, individual D17 cell clones were isolated and expanded.  To
insure that the provirus in the D17 cell clones expressed a functional lacZ, six cell clones
were stained with X-Gal and clones that stained blue were selected for further
manipulation (data not shown).  To verify that the GA-1 provirus was capable of
completing one cycle of retroviral replication, the D17 cell clones were transfected with
pAMS, a plasmid that encodes a replication competent MLV.  After transfection, the
replication competent virus was allowed to spread through the culture for 5 to 7 days.
Virus was harvested and used to transform fresh D17 cells.  The presence of cells that
stained blue with X-Gal after infection indicated that the GA-1 provirus was mobilized
from the D17 cell clones to the target cells in the presence of the MLV helper virus (data
not shown).
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Next, the pSV-A-MLV env was cotransfected with pBSpac (a plasmid that confers
resistance to puromycin) into a D17 cell clone containing a GA-1 provirus.  The
transfected cells were selected for resistance to puromycin and 12 cell clones were isolated
and expanded.  To verify that the cell clones expressed a functional amphotropic MLV
envelope, the cell clones were cotransfected with pLGPS, which expresses the MLV Gag-
Pol proteins (Fig. 1A) and pSVa3.6 (a plasmid that confers resistance to ouabain).
Ouabain resistant cells were selected and virus produced from them was used to infect
fresh D17 cells.  The infected D17 cells were selected for resistance to G418 and stained
with X-Gal (11).  The presence of cells that stained blue with X-Gal indicated that the
D17 cell clones expressed the amphotropic MLV envelope and mobilized the GA-1
provirus to target cells in the presence of MLV Gag-Pol proteins.  All 12 of the D17 cell
clones tested for expression of the amphotropic MLV envelope generated virus titers of at
least 104 CFU/ml after transfection with pLGPS (data not shown).  One of the 12 clones
was chosen and named the ANGIE P encapsidating cell line (Fig. 1B).
It was also important to show that the ANGIE P encapsidating cell line did not
express a replication competent MLV, the presence of which could potentially result in
multiple rounds of GA-1 replication.  Culture supernatant from the ANGIE P
encapsidating cell line was used to infect fresh D17 cells, which were selected for
resistance to G418.  No G418-resistant colonies were observed, indicating that the
ANGIE P encapsidating cell line did not harbor a replication competent virus (data not
shown).  Finally, the ANGIE P cells were plated at a low density (<100 cell/60-mm dish)
and stained with X-Gal.  The frequency of white cells was approximately 1 per 1500 cells,
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indicating that the vast majority of the virus is produced from cells containing a functional
lacZ (data not shown).
To ensure that the ANGIE P encapsidating cell line contained only one GA-1
provirus, genomic DNA was extracted from the ANGIE P cells and analyzed by Southern
blot hybridization (Fig. 1C).  The DNA was digested with either HindIII or NcoI and
hybridized to a probe containing IRES and neo sequences (shown in Fig. 1A).  The
HindIII enzyme cuts once in the GA-1 provirus and two fragments of varying lengths,
representing 5’ and 3’ portions of the provirus and flanking regions, should be generated
from each provirus.  The presence of only two detectable fragments after HindIII
digestion indicated that only one provirus was present in the ANGIE P cells.  Similarly,
the NcoI enzyme cuts once in the GA-1 provirus and one fragment representing the 5’
portion of the provirus and flanking region should be generated from each provirus.  The
presence of one fragment after NcoI digestion verified that only one provirus was present
in the ANGIE P cells (Fig. 1C).  Finally, the sequence of the lacZ in ANGIE P cells was
determined by PCR amplification and DNA sequencing of both strands to insure that no
mutations were present (data not shown).
Experimental protocol.  The MLV RT expression construct pLGPS was
subjected to site directed mutagenesis, and the ANGIE P cells were employed to identify
protein determinants important to the accuracy of DNA synthesis during reverse
transcription (Fig. 1A and B).  First, pLGPS-derived constructs that contained mutations
in the MLV RT were separately introduced into the ANGIE P cells by cotransfection with
pSVa3.6.  Ouabain-resistant colonies were pooled and expanded.  Virus was harvested
from the pools of transfected cells, serially diluted viruses wereused to infect D17 target
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cells.  The infected D17 cells were selected for resistance to G418 and the resulting
colonies were stained with X-Gal.  The frequency of lacZ inactivation was determined by
dividing the number of white colonies by the total number of colonies (blue plus white
colonies).  In general, the multiplicity of infection was < 0.0005, and the probability of
double infection was very low (<1/2000 colonies).  The frequency of lacZ ina tivation
provided a measure of the inactivating mutations introduced into the lacZ ge e during one
cycle of retroviral replication, which constituted the transfer of genetic information from
the GA-1 provirus in the ANGIE P cells to the GA-1 provirus in the D17 target cells.
Using this assay, the effect of introducing mutations in the MLV RT on the fidelity of
DNA synthesis was determined.  In addition, the virus titers obtained after transfections of
wildtype or mutated pLGPS constructs were used to determine the effect of mutations on
the efficiency of virus replication.
Effect of mutations at the V223 position of the MLV YVDD motif on fidelity.
The V223 of MLV RT was mutated to an alanine (V223A), isoleucine (V223I),
methionine (V223M), or serine (V223S) and the effect of these mutations on the
frequency of lacZ inactivation was determined.  The frequencies of lacZ inactivation with
each mutant RT were compared to the frequency of inactivation obtained with wildtype
RT in parallel experiments (Table 1).
The wildtype pLGPS construct inactivated lacZ at an average frequency of 5.2%
in one cycle of retroviral replication.  The frequencies of lacZ inactivation obtained in 10
independent experiments were highly reproducible (S. E. ± 0.48%).  The V223A, V223M,
and V223S mutants exhibited a 1.7-, 1.8-, and 2.3-fold higher frequencies of lacZ
inactivation, respectively, in comparison to wildtype.  The observed frequencies of lacZ
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inactivation with the mutants were shown to be statistically different than wildtype (P <
0.001).  Conversely, the isoleucine mutant showed no significant change in the frequency
of lacZ inactivation (5.3% ± 0.30).  All mutants displayed decreases in viral titers relative
to the wildtype (4.4 ´ 104 CFU/ml), which ranged from 2- to 100-fold (Table 1 and Fig.
2C).  In addition, there was no correlation between reduction in viral titer and fidelity.
Mutational analysis of MLV RT RNase H domain.   Mutations S526A,
Y598V, and R657S were introduced into the MLV RNase H domain, and the effects of
these mutations on the frequency of lacZ inactivation were determined (Table 2).  These
mutations were selected because it was previously shown that they did not affect the
polymerase activity and permitted viral replication to occur (7, 8). Again, the wildtype RT
displayed a 5.2% ± 0.30 frequency of lacZ inactivation.  Mutants R657S and S526A
exhibited frequencies of lacZ inactivation that were increased by 1.2- and 1.4-fold,
respectively (P < 0.005).  In contrast, the Y598V mutant did not exhibit a change in the
frequency of lacZ inactivation (5.4% ± 0.39; P = 0.81).  Finally, all three RNase H domain
mutants exhibited a decrease in the viral titer by 2.5- or 5-fold relative to the wildtype (1.2
´ 105 CFU/ml) (Table 2 and Fig. 2C).  Once again, there was no correlation between
reduction in viral titer and fidelity.
Reverse transcriptase activities of mutant RTs.  Viruses produced from the
wildtype and mutant RTs were harvested by ultracentrifugation and characterized by
Western blotting analysis using an anti-MLV capsid antibody (13).  The Western blots
were quantified to estimate the amounts of MLV capsid protein present in the viral
preparations.  A representative blot is shown in Fig. 2A.  The estimated amounts of capsid
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protein were utilized to insure that equivalent amounts of viral proteins were used for
determination of reverse transcriptase activities (Fig. 2B).  The reverse transcriptase
activities ranged from 5% ± 1% for the V223A mutant to 93% ± 1 for the S526A
mutant, relative to the wildtype enzyme.  As expected, all of the RNase H domain mutants
exhibited RT activities that were comparable to the wildtype RT.  With the exception of
the V223I mutant, all of the reductions in the reverse transcriptase activities were
significantly different from the wildtype (P < 0.005).
The reverse transcriptase activities were compared to the relative reductions in
viral titers observed (Fig. 2C).  In general, the reductions in reverse transcriptase activities
were proportional to the reductions in viral titers observed for the V223 mutants.  As
expected, the RNase H mutants exhibited higher reverse transcriptase activities than most
of the V223 mutants at the polymerase active site.  In general, the RNase H mutants
displayed a greater reduction in the viral titer relative to the reverse transcriptase activities,
suggesting that other steps in the reverse transcription process were affected by mutations
introduced in the RNase H domain.
Analysis of lacZ inactivating mutations.  To determine the nature of mutations
introduced into the lacZ gene by the wildtype or mutant RTs, 161 infected G418-resistant
cell clones were isolated from infections performed with the wildtype RT as well as the
V223A, V223M, and the Y598V mutants.  X-Gal staining of the clones indicated that 11
of 161 cell clones exhibited a white colony phenotype.  One mutant clone was derived
from infection with the wildtype RT, three were derived from infection with the V223A
mutant, three were derived from infection with the Y598V mutant, and four were derived
from infection with the V223M mutant.  The lacZ sequences from these 11 white colonies
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was amplified by two rounds of PCR using six different sets of primers.  As a result, 3
overlapping fragments designated the 5’, the middle, and the 3’ portions were generated
(Fig. 3A).  The PCR products were approximately 1.2 to 1.3 kb in length.  Each of the
PCR fragments derived from the 11 cell clones were analyzed by gel electrophoresis and
compared to the fragments obtained from a cell clone containing a functional lacZ. This
analysis indicated that none of the lacZ g nes present in the 11 cell clones were inactivated
by large deletions or insertions (> 100 bp; data not shown).  The amplified lacZ fr gments
were digested with various restriction enzymes to generate smaller fragments in an effort
to identify shorter deletions or insertions (Fig. 3B).  Both the 5’ and 3’ fragments of the
lacZ from infected cell clones were digested with BstUI, HaeIII, and HhaI.  The middle
portion was digested with DpnII, HpaII, and NlaIII.  DNA fragments that ranged in size
from 75 to 863 bp were analyzed by gel electrophoresis.  No differences were observed in
any of the restriction digestions, indicating that the lacZ inactivating mutations did not
involve deletions or insertions that were larger than 20 bp (based on the estimated
resolution the restriction analysis).
Since no small deletions or insertions could be observed, both strands of the PCR
products derived from 3 cell clones were sequenced to insure the accuracy of the
sequencing analysis.  These three cell clones that displayed a white colony phenotype were
derived from an infection with the V223A mutant of MLV RT.  The sequencing analysis
indicated that two mutants contained a +1 frameshift in runs of 6 adenosine nucleotides
present at different locations in the lacZ g ne.  One mutant contained a C to T transition,
which resulted in the generation of a termination codon.  These mutations were not the
result of errors occurring during the PCR reactions, since they were identified in
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independent PCR reactions (data not shown).  These results verified that the white colony
phenotype was indeed generated by introduction of mutations in lacZ.  I  addition,
different types of mutations could be identified in this assay (Fig. 3C).
DISCUSSION
This study provides a rapid, accurate, and highly reproducible in vivo assay for
identification of MLV RT structural determinants important for fidelity.  The in vivo assay
described here is rapid in comparison to the previously described in vivo assays involving
shuttle vectors because the mutant frequencies can be determined immediately after the
infected cell clones are obtained (42, 43, 53, 54).  This assay is also more sensitive and
accurate than the previously described in vivo assay utilizing the herpes virus thymidine
kinase reporter gene because it is not necessary to compare viral titers after two different
drug selection procedures (52). Due to the large size of the lacZ reporter gene, a high
mutant frequency is obtained and a large number of mutants can be identified.  The high
mutant frequency increases the utility of the assay because the accuracy of RT mutants
with low viral titers can be easily determined.  In addition, mutations that increase the
accuracy of DNA synthesis can also be identified.  One limitation of this in vivo assay is
that RT mutants with extremely low fidelities may generate highly mutated viruses that
can not confer resistance to G418 and therefore can not be analyzed.
The results of these studies indicate that mutations at the V223 position of the
MLV RT have a statistically significant effect on the in vivo fidelity of RT.  These results
are consistent with the in vitro forward mutation assays performed with the YVDD mutant
of HIV-1 RT (19).  For both MLV and HIV-1 RTs, the YVDD motif appears to be
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approximately twofold more accurate than the YMDD motif.  It is possible that even
though the overall mutation rate is altered by only twofold, the rate of a specific type of
mutation is altered to a greater extent.  For example, a 10-fold increase in the rate of one
of the twelve possible substitutions may have a less than twofold effect on the overall
mutation rate.
The effect of a twofold alteration in the retroviral mutation rate on variation in
viral populations is undetermined.  A model was previously proposed to ascertain the
relative impact of mutation rates and selective forces on viral populations (14).  Based on
the model, it was hypothesized that in a large viral population with a high replicative
capacity, small changes in the selective forces will have a greater impact on the viral
variants present than large changes in mutation rates.  Whether small changes in the
mutation rate will affect viral evolution will be dependent on the size of the viral
population and its growth potential.  In this regard, it is significant that the rate of
development of drug resistant variants in cell culture was the same for the YMDD and the
YVDD variants of HIV-1 (32, 49).  This observation, along with the observation that the
YVDD variant is only twofold more accurate than the YMDD variant, suggests that
twofold alterations in RT fidelity are unlikely to have an effect on the rate of viral
evolution.
It is of interest to consider the structural features of the YMDD and YVDD
variants and how these features may be related to the statistically significant alterations in
fidelity.  It has been postulated that the X residue of the YXDD motif may contact the
primer and is important for affinity to the template-primer as well as its positioning relative
to the catalytic site (10, 17, 59).  Repositioning of the template-primer by the YMDD
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variant may alter flexibility of the dNTP binding pocket, ultimately leading to changes in
fidelity (27).  In addition, molecular modeling studies have predicted an increased fidelity
of YVDD and YIDD variants due to new contacts with the incoming dNTP substrate that
are absent from the YMDD variant (29, 51).  Therefore, the hydrophobicity and the size
of the amino acid side chain at the V223 position may be important for the catalytic
function and fidelity of RT.  It is interesting to note that 2 of the 3 mutations generated
with the V223A mutant RT were +1 frameshifts.  Frameshifts account for approximately
10% of all mutations (42, 54), and this limited analysis suggests that the V223A mutation
may affect the template-primer affinity and frameshift fidelity, which is consistent with
previous observations (10).
 The observation that the V223A mutant exhibits a severe reduction in the
polymerase activity whereas the V223I mutant has little effect on the polymerase activity
is consistent with previously published results obtained with HIV-1 RT (10).  Also, the
viral titers were consistently reduced to a greater extent than the observed decreases in
polymerase activities, suggesting that additional steps during reverse transcription may
also be affected by the mutations.
The RNase H mutants S526A and R657S exhibited small but statistically
significant alterations in fidelity.  As expected, the mutations had little effect on the
polymerase activity (8).  The changes in fidelity of these mutants may be due to altered
processivity of RT, interactions of the RT with the template-primer complex, or the
overall structure of the RT (24, 61).  The reductions in viral titers associated with these
mutants may be due to a reduced efficiency of strand transfer events during reverse
transcription (21, 41).
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The assay described here may be utilized to determine the role of various RT
domains, including the dNTP binding site and the thumb domain, in the fidelity of reverse
transcription.  The importance of other viral proteins to the fidelity of reverse transcription
may also be easily determined.  Finally, a similar strategy may be utilized to analyze the
effect of mutations in RT on the frequencies of specific types of mutations.
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TABLE 1.  The effects of V223 mutations in the YVDD motif of MLV RT on the
frequency of lacZ inactivation
MLV-RT
Genotype
No. of
Expts
No. Mut.
Colonies/Total
Coloniesa
Frequency
of lacZ
Inactivation
(%± S.E.)b
Relative
Change in
Inactivation
of lacZc
Relative
Viral Titerd
Wt 10 154/2,860 5.2 ± 0.48 1.0 1.0
V223A 6 207/2,289 8.8 ± 0.45 1.7 0.03
V223I 2 95/1,764 5.3 ± 0.30 1.0 0.50
V223M 4 182/1,974 9.2 ± 0.36 1.8 0.12
V223S 4 200/1,632 12.1 ±  0.43 2.3 0.01
a The number of mutant colonies that displayed a white colony phenotype and the total
number of colonies that were observed in 2 to 10 independent experiments.
b The frequency of lacZ inactivation was calculated as follows:  No. mutant colonies in
each experiment ¸ by total number of colonies ´ 100%.  The standard errors were
determined by using the Two-Sample T-Test.
c The relative change in the frequency at which the lacZ gen was inactivated was
calculated as follows: frequency of la Z inactivation observed with mutant MLV RT ¸ by
frequency of lacZ inactivation observed with wildtype MLV RT.  Statistical analysis using
a Two-sample T-Test showed that V223M, V223S, and YADD mutants of MLV RT
displayed a significantly higher mutant frequency in comparison to the wildtype MLV RT
(P <  0.001).  The mutant frequency obtained with the YIDD mutant of MLV RT was not
significantly different from the wildtype MLV RT (P = 0.71).
d Virus titer for each experimental group was determined by serial dilutions and infections.
The average virus titer obtained with wildtype MLV RT was 4.4 x 104 CFU/ml.  The
relative virus titer represents a ratio of the virus titer of mutant MLV RT obtained in each
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experiment divided by the virus titer obtained with wildtype MLV RT in parallel
experiments.
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TABLE 2.  The effects of mutations in the RNase H domain of MLV RT on the frequency
of lacZ inactivation
MLV-RT
Genotype
No. of
Expts
No. Mut.
Colonies/Total
Coloniesa
Frequency
of lacZ
Inactivation
(%± S.E.)b
Relative
Change in
Inactivation
of lacZc
Relative
Viral Titerd
Wt 9 473/8,023 5.2 ± 0.30 1 1.0
S526A 5 429/5,039 8.4 ± 0.33 1.6 0.25
Y598V 4 181/3,534 5.4 ± 0.39 1 0.40
R657S 5 344/4,754 7.1  ± 0.14 1.4 0.21
a The number of mutant colonies that displayed a white colony phenotype and the total
number of colonies that were observed in 4 to 9 independent experiments.
b The frequency of lacZ inactivation was calculated according to Table 1.
c The relative change in the frequency at which the lacZ gen was inactivated was
calculated at described in Table 1.  Statistical analysis using a Two-Sample T-Test showed
that S526A and R657S mutants of MLV RT displayed a significantly higher mutant
frequency in comparison to the wildtype MLV RT (P < 0.005).  The mutant frequency
obtained with the Y598V mutant of MLV RT was not significantly different from the
wildtype MLV RT (P = 0.81).
d Virus titer for each experimental group was determined by serial dilutions and infections.
The average virus titer obtained with wildtype MLV RT was 1.2 x 105 CFU/ml.  The
relative virus titer represents a ratio of the virus titer of mutant MLV RT obtained in each
experiment divided by the virus titer obtained with wildtype MLV RT in parallel
experiments.
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FIG. 1.  Structures of MLV-based constructs and rapid in vivo assay to identify structural
determinants in MLV RT important for fidelity.  (A) Structures of MLV-based vector
pGA-1, pLGPS, and pSV-A-MLV-env.  The pGA-1 vector contains long terminal repeats
(LTRs) and all cis-acting elements of MLV.  pGA-1 transcribes the E. coli lacZ and neo
from the LTR promoter.  The internal ribosomal entry site (IRES) of
encephalomyocardidtis virus is used to express neo.   The construct pLGPS expresses the
MLV gag and pol from a truncated viral LTR.  Finally, the pSV-A-MLV-env expresses
the amphotropic MLV envelope from a truncated MLV LTR and the SV40 promoter
enhancer.  (B)  Experimental protocol. ANGIE P, a D17-based cell line expressing pGA-1
and amphotropic MLV envelope, was constructed.  The wildtype or mutated pLGPS were
separately cotransfected with pSVa3.6 into the ANGIE P cell line and the virus produced
was used to infect D17 cells.  The infected cell clones resistant to G418 were stained with
X-Gal and the numbers of blue (wildtype) and white (mutant) colonies were determined.
(C)  Southern analysis of the ANGIE P encapsidating cell line.  Genomic DNA isolated
from ANGIE P cells was digested with either HindIII (lane H) or NcoI (lane N). The blots
were probed with IRES-neo (black bar, Fig. 1A) and quantitated by PhosphorImager
analysis.
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FIG. 2.  Comparison of RT activities and viral titers.  (A)  Representative Western blot
analysis of the wildtype and V223 mutants used to normalize the amount of viral proteins
used in the RT assays.  (B) Reverse transcriptase activity using virion-associated RT.  The
activities shown are relative to the RT activity determined for the wildtype MLV RT (set
to 100%).  The results represent an average of 2 to 3 experiments.  The error bars
represent the standard error of the mean.  (C) Summary of virus titers obtained relative to
the wildtype viral titer (set to 100%).  The results represent an average of 2 to 10
experiments and the error bars represent the standard error of the mean.
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FIG. 3.  PCR analysis of lacZ mutations in proviral DNAs of infected cell clones.  (A)
Structure of lacZ and approximate locations of the overlapping PCR amplified products.
The approximate locations of 5’, middle, and 3’ fragments generated during PCR
amplification of lacZ are shown.  (B) Representative restriction digestion analysis of PCR
products obtained from infected cell clone 6W.  The 5’ and 3’ fragments were digested
with BstUI (B), HaeIII (Ha), and HhaI (Hh).  The middle fragment was digested with
DpnII (D), HpaII (Hp), and NlaIII (N).  The odd numbered lanes represent PCR products
from a cell clone containing wildtype acZ.  The even numbered lanes represent PCR
products derived from cell clone 6W containing an inactivated lacZ.  (C) lacZ inactivating
mutations in infected cell clones 1W (3330-3343 nt), 2W (3666-3680 nt), and 3W (4085-
4099 nt).  Inactivating mutations are shown in bold type.  A +1 frameshift mutation in a
run of 6 A nucleotides is shown (labeled +A).  A substitution mutation (C to T) is shown
(labeled T).
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ABSTRACT
Retroviral populations exhibit a high evolutionary potential giving rise to
extensive genetic variation.  A mechanism that generates variation in retroviral
populations may be error-prone DNA synthesis catalyzed by reverse transcriptase
(RT).  Structural features within RTs are likely to contribute to the high rate of
errors that occur during reverse transcription.  We sought to determine whether
amino acids within murine leukemia virus (MLV) RT that contact the
deoxyribonucleotide triphosphate (dNTP) substrate are important for fidelity of
reverse transcription in vivo.   We utilized the previously described ANGIE P
encapsidating cell line, which expresses the amphotropic MLV envelope and a
retroviral vector (pGA-1).  pGA-1 expresses the bacterial b-galactosidase gene
(lacZ), which serves as a reporter of mutations.  Extensive mutagenesis was
performed on residues likely to interact with the dNTP substrate and the effects of
these mutations on the fidelity of reverse transcription were determined.  As
expected, most substitution mutations at positions believed to directly interact with
the dNTP substrate significantly reduced viral titers (> 10,000-fold), indicating that
these residues played a critical role in catalysis and viral replication.  However, the
D153A and A154S substitutions, which are predicted to affect the interactions with
the triphosphate, resulted in statistically significant increases in the mutation rate.
In addition, the conservative substitution F155W, which may affect interactions
with the base and the ribose, increased the mutation rate 2.8-fold.  Substitutions at
residues in the vicinity of the dNTP-binding site also resulted in statistically
significant decreases in fidelity (1.3- to 2.4-fold).  These results suggest that
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mutations of residues that contact the substrate dNTP are more likely to prevent
viral replication than to alter the fidelity of RT.
INTRODUCTION
Retroviral populations display extensive genetic variability that can be attributed
to properties of the virally encoded reverse transcriptase (RT).  The innate ability of RT
to be less processive than most polymerases and/or the lack of a 3¢-5¢ exonuclease
activity (proofreading mechanism), may allow for the reduction of accurate DNA
synthesis (37, 42).  It has been observed in vivo that at least 1/3 of the generated
mutations occur during the plus-stand DNA synthesis of reverse transcription (28).
Therefore, errors generated by RT may contribute to the variation in viral populations as
seen with human immunodeficiency virus type 1 (HIV-1) (5).  Several amino acid motifs
present in different retroviral RTs have been identified that may exert an impact on the
fidelity of DNA synthesis during reverse transcription.  These include residues of the
Tyr-X-Asp-Asp (YXDD) motif, the deoxyribonucleotide triphosphate (dNTP) binding
site, the a H helix of the thumb domain, the conserved Leu-Pro-Gln-Gly (LPQG) motif,
the fingers domain, as well as specific amino acids such as E89 and F160 in HIV-1 RT
(1, 3, 4, 9, 11, 14-16, 26, 33, 39, 47).  The mechanism by which fidelity is maintained
may encompass subtle features in RT that involve the local geometry of the active site,
the proper positioning of the template-primer complex, or the global effects attributed to
different conformational states of the protein (7, 16).
It was previously shown that residues 110 to 116 in HIV-1 RT are located in the
active site of RT and have a moderate to high solvent accessibility, suggesting that they
may play a role in dNTP binding (20, 41).  Furthermore, extensive mutational analysis of
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residues Y115 and Q151 in HIV-1 RT revealed that substitutions could have drastic
effects on substrate dNTP binding (33, 39) as well as play a role in resistance to
nucleoside analogs (19, 43).  Resistance to nucleoside analogs has also been observed
with position 116 as well (45).  Additional evidence for the importance of this stretch of
residues in dNTP binding and catalysis was provided by the ability of the D113 and A114
mutants of HIV-1 RT that exhibit a decrease in the sensitivity to phosphonoformic acid
(PFA), a pyrophosphate analog (31).  It was hypothesized that these residues, in addition
to the highly conserved R72, play an important role during pyrophosphate exchange (31,
40).  Finally, mutations at K65 have implicated this residue in template-primer complex
binding that may ultimately have effects on fidelity (13, 29, 41).
Recently, the structure of a ternary complex of HIV-1 RT catalytically trapped with
both template-primer and deoxyribonucleotide thymidine triphosphate (dTTP) substrates
was elucidated, which identified the residues that directly contacted the incoming dNTP
(18).  These included residues K65, R72, D113, A114, Y115, and Q151 of HIV-1 RT.
The K65 and R72 side chains as well as the D113 and A114 main chain amide nitrogens
(NH) bind to the a, b and g  phosphates of the incoming dTTP through hydrogen bonding
interactions.  In addition, it has been illustrated that the side chains of R72, Y115, and
Q151 interact with the base of the dTTP.  Finally, the main chain NH of residue Y115
was also shown to be in close proximity to the ribose moiety of the dTTP (18).
Since substrate dTTP and the aforementioned amino acids are in close proximity to
each other, it is reasonable to hypothesize that substitutions at these positions may alter
the binding of the incoming dNTP, positioning of the template-primer complex, or
modify the local geometry of the substrate binding pocket (16).  This alteration in turn
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can lead to changes in fidelity.  This hypothesis is supported by evidence from mutations
introduced at positions K65 and Q151 of recombinant HIV-1 RT, which exhibited
decreased mispair extension in vitro as well as resistance to a number of
dideoxynucleoside analogs such as 2¢,3¢-dideoxy-3¢-thiacytidine (3TC), 3¢-azido-3¢-
deoxythymidine (AZT), 2¢,3¢-dideoxycytidine (ddC), and 2¢,3¢-dideoxyinosine (ddI) (12,
16, 44).  Finally, a number of mutations introduced at residue Y115 of HIV-1 RT were
shown to affect the frequency of misinsertions and mispair extensions (33, 34).
Primary sequence and crystal structure data can be utilized to identify amino acids in
murine leukemia virus (MLV) RT that are equivalent to those in HIV-1 RT.  Sequence
comparisons of several RTs illustrate the presence of highly conserved amino acid motifs
(36).  The partial structure of the fingers and palm subdomains of MLV RT has been
solved (11).  Comparison of the fingers and thumb subdomains of HIV-1 and MLV RTs
reveal similar tertiary structures despite having only ~25% amino acid sequence identity
(11, 17).  Furthermore, MLV RT possesses several of the structural motifs present in
HIV-1 RT, including the conserved YXDD, the Thr-Val-Leu-Asp (TVLD), and LPQG
motifs (11, 36).  Sequence alignment of common amino acid motifs within the two RTs
and a comparison of the crystal structures reveal MLV RT residues that are homologous
to those in HIV-1 RT (11, 17).  Such comparisons strongly suggest that residues K103,
R110, D153, A154, F155, and Q190 of MLV RT are equivalent to the dTTP binding
residues K65, R72, D113, A114, Y115, and Q151 in HIV-1 RT, respectively.
Furthermore, K103 of MLV RT has been observed to interact with the incoming dNTP,
and substitutions at R110 affect processivity (2, 7).  It has been postulated that F155 of
MLV RT may be involved in the selection of dNTPs over ribonucleotides (rNTPs) due to
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steric hindrance between the 2¢ OH of rNTP and the F155 side chain (11).  More recent
studies have provided direct evidence that the F155V mutant of MLV RT is able to
incorporate rNTPs during polymerization (10).
In this study, we sought to determine whether alterations in the structure of MLV RT
could affect the fidelity of reverse transcription in vivo.  Specifically, we examined
whether mutations at residues in the vicinity of the dNTP binding pocket as well as
residues that directly contact the substrate dNTP could alter the fidelity of reverse
transcription in vivo.  We assessed the effects of these mutations on replication,
polymerase activity, and fidelity by comparing the mutant MLV RTs to wild-type RT.
MATERIAL AND METHODS
Plasmids and retroviral vectors.  The construction of the MLV-based retroviral
vector pGA-1 was previously described (23).  The vector pGA-1 possesses cis-acting
elements needed for viral replication.  In addition, the vector expresses the bacterial b-
galactosidase gene (lacZ) and the neomycin phosphotransferase gene (neo) from a single
RNA transcript initiating from the viral promoter.  An internal ribosomal entry site
(IRES) of encephalomyocarditis virus is used to insure for the translation of neo (21).
Plasmid pLGPS expresses the MLV gag and pol genes from a truncated long terminal
repeat (DLTR) promoter (35).  Plasmid pRMBNB, which was derived from pLGPS,
contains three unique restriction sites (Bst1107I, NsiI, and BstBI) near the dNTP-binding
site of MLV RT.  These three restriction sites were generated by the introduction of silent
substitutions to facilitate further mutagenesis.  The plasmid pSV-A-MLV-env, which
expresses the amphotropic MLV envelope gene from the LTR promoter and SV40
enhancer, was obtained from the NIH AIDS Research and Reference Reagents Program
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(30).  Plasmid pBSpac encodes the puromycin N-acetyltransferase gene and therefore
confers resistance to puromycin (46).  Plasmid pSVa3.6 encodes the a subunit of the
murine Na+, K+-ATPase gene and confers resistance to ouabain (25).
Generation of dNTP-binding site MLV RT mutants.  A detailed description of
the mutagenic oligonucleotides and strategies used to generate as well as identify mutants
is available upon request.  Briefly, pRMBNB was generated by two rounds of site-directed
mutagenesis using the Chameleon kit (Stratagene) with mutagenic primers and pLGPS as
the template.  pRMBNB was screened by the presence of three unique restriction sites,
Bst1107I, NsiI, and BstB1.  To ensure the absence of any undesired mutations, the BclI to
SalI DNA fragment of pRMBNB was subcloned into pLGPS.  In addition, the Q190E,
Q190H, and Q190N mutants were generated in a similar manner using the Chameleon kit
(Stratagene) with either pLGPS or pRMBNB as the templates and the appropriate
mutagenic primers.  The Q190E mutant was generated utilizing pLGPS as the template and
screened by the creation of a new Bsu36I site.  The BclI to SalI DNA fragment of Q190E
was subcloned into pLGPS to ensure the absence of any undesired mutations.  The Q190E
mutant, designated as pESQ190E was also generated in pRMBNB and screened by the
creation of a new Bsu36I site.  Both the Q190H and Q190N mutants were generated using
the Chameleon kit (Stratagene) with pESQ190E as the template and screened by the loss of
the new Bsu36I site.  The NsiI to SalI DNA fragments of Q190H and Q190N were
subcloned into pRMBNB to ensure the absence of any undesired mutations.
PCR-based mutagenesis with random mutagenic primer sets and pRMBNB as the
template was utilized to generate mutants at residues K103 and R110.  Amplified DNA
fragments of 493 bp were digested with BclI andNsiI and subcloned back into pRMBNB.
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In addition, the Q190M mutant was generated in a similar manner using PCR-based
mutagenesis utilizing mutagenic primers and screened by sequencing.  An amplified DNA
fragment of 831 bp was digested with NsiI and SalI and subcloned back into pRMBNB.
Mutations introduced at positions 147 to 160 of MLV RT were generated by
double-stranded DNA oligonucleotide (dsDNA oligo)-based mutagenesis.  These various
dsDNA oligos, which are complementary to the Bst1107I to BstBI fragment in pRMBNB
and contain the appropriate mutations, were subcloned back into pRMBNB.  One or two
silent mutations were also introduced into these oligonucleotides to generate new
restriction sites to facilitate identification of mutant plasmids.  Mutations introduced at
positions 147 to 153 of MLV RT were generated by replacing the Bst1107I to NsiI
fragment of pRMBNB with 25-bp dsDNA oligos.  Mutations introduced at positions 154
to 155 were generated by replacing the Bst1107I to BstBI fragment of pRMBNB with 73-
bp dsDNA oligos.  Mutations introduced at positions 155 to 160 were generated by
replacing the NsiI to BstBI fragment of pRMBNB with 48-bp dsDNA oligos.  Mutants
were identified by digestion with either XbaI (mutants at positions 147 to 155) or SpeI
(mutants at positions 156 to160).
Finally, all mutated plasmids were mapped extensively utilizing various
restriction enzymes. In addition, mutated plasmids with inserted fragments containing
the appropriate mutations, were analyzed by DNA sequencing (ALF Automated
Sequencer, Pharmacia) to verify the presence of the desired mutation and the absence
of any undesired mutations.
Cells, transfections, and infections.  D17 dog osteosarcoma cells were
transfected with either the MLV-based vector or expression constructs or infected with
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MLV and selected for resistance to ouabain or G418 (a neomycin analog) as previously
described (22, 23).  The D17-based ANGIE P cells were maintained, transfected, and
selected for drug resistance in a similar manner (15).
Assay for determining in vivo fidelity.  The ANGIE P cells were plated at a
density of 2 ´ 105 cells per 60-mm-diameter dish, and 24 h later were cotransfected
with wild type or mutated pLGPS and pSVa3.6.  The transfected cells were selected for
resistance to ouabain (10-7M), then resistant colonies were pooled, expanded, and
plated at a density of 5 ´ 106 cells per 100-mm-diameter dish.  After 48 h, the culture
medium containing GA-1 virus was harvested and used to infect D17 target cells plated
at a density of 2 ´ 105 cells per 60-mm-diameter dish.  Infected D17 cells were selected
for resistance to G418 (400 mg/ml) and stained with 5-bromo-4-chloro-indolyl-b-D-
galactopyranoside (X-Gal) as previously described (15).
Virus preparation, RT assays, and Western blotting.  Virus isolation and
concentration as well as RT assays, and Western blots were performed as previously
described (15).  Briefly, helper cells containing different pLGPS constructs were plated
at 5 ´ 106 cells per 100-mm dish, viruses were collected 2 days later and centrifuged at
25,000 rpm for 90 min in an SW41 rotor (Beckman) at 4ºC.  Viral pellets were
resuspended in phosphate-buffered saline (PBS) and virus was stored at –80º C.
Exogenous RT activities were determined as previously described using 50 mg/ml
of (20-mer) oligo (dT) (Integrated DNA Technologies), 100 mg/ml of poly (rA)
(Pharmacia), and 10 mCi of [3H] dTTP (specific activity of 72 Ci/mMol, ICN).  The
amount of [3H] dTTP incorporated was determined using a scintillation counter (13).
94
Western blots were used to quantify the amount of protein for the RT assays and
performed using standard procedures (38).  Briefly, virus was resolved using a 15%
SDS-PAGE and proteins were transferred to Immobilin Membranes (Gelman Sciences,
Inc.).  Membranes were incubated with primary (monoclonal anti-MLV capsid IgG1;
1:10 dilution [ATCC]) (6) and secondary (anti-rat IgG antibody conjugated to
horseradish peroxidase; 1:10,000 dilution [Southern Biotechnology Associates, Inc.])
antibodies and detection of MLV capsid was performed using an ECL (enhanced
chemiluminenesence) kit TM (Amersham Pharmacia Biotech). Treated membranes were
then exposed to X-OMAT film (Kodak) and the intensity of the p30 band was
quantitated using the Image Quant program (Molecular Dynamics) (15).
RESULTS
Determination of in vivo fidelity.  Construction and characterization of the
ANGIE P cell line has been previously described (15).  Briefly, the ANGIE P cell line
expresses the MLV-based retroviral vector pGA-1 and the MLV envelope expression
construct pSV-A-MLV-env (Fig. 1).  The MLV gag/pol expression construct pLGPS was
subjected to site-directed mutagenesis at residues constituting the dNTP-binding site of
MLV RT and subsequently, wild type or mutated pLGPS was separately introduced into
the ANGIE P cells by cotransfection with pSVa3.6.  Ouabain-resistant colonies were
pooled and expanded; virus was harvested from these pools and serially diluted, which
was used to infect D17 target cells.  Infect D17 cells resistant to G418 were selected,
stained with X-GAL, and the frequency of la Z inactivation was determined by dividing
the number of white colonies by the total number of colonies (blue plus white colonies).
The frequency of lacZ inactivation provided a measure of the inactivating mutations
95
(white phenotype) introduced into the lacZ gene during one cycle of retroviral replication
and the virus titers were used to determine the effect of mutations on the efficiency of
virus replication.
Identification of the dNTP-binding site in MLV RT.  Comparison of both HIV-
1 and MLV RT revealed the dNTP-binding site in MLV RT.  Amino acid sequence
alignment of HIV-1 and MLV RTs revealed the highly conserved TVLD, DAXF, and the
LPQG motifs (Fig. 2A).  This sequence comparison suggested that residues K103, R110,
D153, A154, F155, and Q190 of MLV RT are equivalent to residues K65, R72, D113,
A114, Y115, Q151 of HIV-1 RT, respectively.  Analysis of the crystal structures in the
context of the position and orientation of these residues also revealed similarities between
the two RTs (Fig. 2B and C).  In addition, bond distances calculated between residues
constituting the dNTP-binding sites of both RTs (absence of ligands) (11, 17) showed
that most distances are within 3 Å, the length of a hydrogen bond (data not shown).  The
only distances greater than 3 Å involve the R110 position.  These lengths were
determined by the RasMol program and are characterized as an average bond distance
calculated from a number of measurements between the various atoms of the side chain
pairs inspected.  The equivalence of these MLV RT residues with those in HIV-1 RT is
further supported by previous studies (2, 7, 11, 36).
Mutational analysis of the MLV RT dNTP-binding site and effects on
fidelity.  MLV RT was mutated at six different residues hypothesized to contact the
incoming dNTP.  Several conserved and non-conserved substitutions were introduced at
residues K103, R110, D153, A154, F155, and Q190 of MLV RT.  The effects of these
various mutations on the frequency of lacZ inactivation were determined and compared
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with the frequency of inactivation obtained with wild-type MLV RT in parallel
experiments (Table 1).  The wild-type pLGPS construct inactivated lacZ at n average
frequency of 5.4% and SE ± 0.23% (13 independent experiments) during one cycle of
retroviral replication. These results were comparable to results obtained previously (15).
As illustrated in Table 1, the majority of mutations introduced at these positions
dramatically reduced viral replication, evident as a greater than 10,000-fold reduction in
viral titers in comparison to the wild-type RT (9.8 x 104 CFU/ml).  Relative changes in
the inactivation of lacZ could therefore not be determined.  Mutants with severe
reductions in titer (> 10,000-fold) were observed for all dNTP-binding site positions
analyzed.  Our results suggest that these amino acid positions are critical for the proper
function of the polymerase, consistent with previous observations showing that they are
highly conserved among retroviral species (36).  However, nine mutants of residues
constituting the dNTP-binding site in MLV RT did permit viral replication to the extent
that relative changes in fidelity could be measured.  Three of the nine mutants (A154S,
D153A, and F155W) exhibited increases in the frequency at which lacZ was inactivated
by 1.3- to 2.8-fold relative to the wild-type RT (5.4% ± 0.23%).  These changes were
shown to be statistically different from the frequency of lacZ inactivation by the wild-
type RT (P values ranging from 0.03 to 0.00003 by a Two Sample T-Test).  In addition,
these mutations also reduced viral titers 66- to 2500-fold in comparison to wild-type RT.
Conversely, six of the nine mutants (K103R, D153C, D153Q, D153S, F155Y, and
Q190M) did not display a significant change in the frequency of lacZ inactivation (5.1%
± 0.15% to 5.7% ± 0.23%) and were shown to be similar to wild-type RT (P > 0.5). The
K103R, D153C, D153Q, and D153S mutants also exhibited decreases in viral titers
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ranging from 25- to 1429-fold in comparison to the wild-type RT (Table 1).  In contrast,
the F155Y and Q190M mutants exhibited virus titers similar to wild-type MLV RT.
Previous observations have shown that a 2-fold alteration in viral titers is not believed to
be significant, considering the inherent variation occurring during infections (15).
Effects of mutations at the F156 position of MLV RT on fidelity.  We
hypothesized that the F156 residue of MLV RT played an indirect role in substrate
binding because of its proximity to other residues that constitute the dNTP-binding site.
Specifically, analysis of the MLV RT crystal structure suggested that the bulky
hydrophobic nature of F156 might play a role in the proper positioning of Q190, which is
important for dNTP binding.   Therefore, we investigated the effects of seven mutations
(F156I, F156L, F156M, F156Q, F156V, F156W, and F156Y) of this residue in MLV RT
on the frequency of lacZ inactivation and viral replication (Table 2).  As expected,
substitutions at the F156 position were tolerated to a greater extent than residues believed
to be in direct contact with the incoming dNTP.  Five of the seven F156 mutants
replicated at levels in which their effects on fidelity could be determined.  The F156L and
F156M mutants exhibited increases in the frequency with which lacZ was inactivated by
1.6- and 1.7-fold relative to the wild-type RT (5.4% ± 0.25; obtained from 8 independent
experiments).  These changes were shown to be statistically different from the frequency
of lacZ inactivation by the wild-type RT (P < 0.001).  Both the F156Y and F156W
mutants of MLV RT displayed a slight increase in fidelity as evidenced by the
frequencies of lacZ inactivation of 4.3% ± 0.27% and 4.3% ± 0.15%, respectively when
compared to wild-type MLV RT  (P < 0.05).  All of these mutants displayed reductions
in viral titers relative to the wild-type RT (8.1 x 104 CFU/ml) that ranged from 22- to
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500-fold.  Finally, the F156I, F156Q, and F156V mutants displayed reductions in virus
titers greater than 10,000 fold and relative changes in fidelity for these mutants could not
be determined (Table 2).
Effects of mutations at residues flanking the MLV RT dNTP-binding site on
fidelity.  Regions of MLV RT (positions 147 to 152 and 157 to 161) flanking the residues
of the dNTP-binding site were also subjected to mutagenesis, and the effects of these
mutations on the fidelity of reverse transcription and viral replication were determined.
The data obtained are summarized in Table 3.  The frequencies of lacZ i activation by
wild-type MLV RT obtained from six independent experiments were again highly
reproducible (5.3% ± 0.26%).  The H161A, T147A, C157A, K152A, and L151F mutants
exhibited frequencies of lacZ inactivation that were 1.2-, 1.3-, 1.3-, 1.4-, and 2.4- fold
higher than that of the wild-type RT, respectively.  All five of these mutants displayed
alterations in fidelity that were statistically different from that of wild-type RT (P values
ranging from 0.04 to 0.000009).  On the other hand, the R159A mutant was found to be
statistically similar to wild-type RT (P > 0.05).  The L151F and the T147A mutants
displayed an 8- and 50-fold reduction in viral titers, respectively.  In contrast, the K152A,
C157A, and H161A mutants did not exhibit substantial changes in viral titers.  Finally,
viral replication of the V148D, L149W, and D150E mutants could not be detected, as
evidenced by a greater than 10,000-fold reductions in viral titers. Therefore, the
frequency of lacZ inactivation for these mutants could not be determined (Table 3).
RT activities of the dNTP-binding site mutant RTs.  Viruses generated from
either wild type or mutated pLGPS were harvested, concentrated by ultracentrifugation,
and analyzed by Western blotting (data not shown).  Western blots using an anti-MLV
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capsid antibody were quantified to estimate the amount of capsid protein present in the
viral preparations and to ensure that equivalent amounts of viral proteins were used for
determination of RT activities (summarized in Table 4).
In general, mutants (31 out of 50) possessing RT activities of less than 3% of the
wild-type RT activity also had drastic reductions in viral titers (> 10,000-fold or 0.01%,
relative to wild type).  Only the F156L mutant displayed an RT activity of 2.4% relative
to wild type yet produced a low but detectable viral titer (0.6% in comparison to wild
type).  In addition, the F155I and F155V mutants displayed slightly higher RT activities
(4.9 and 5.5%, respectively), but did not produce a detectable viral titer.  The RT
activities of the remaining 18 mutants ranged from 5.5 to 161.4% relative to the wild-type
MLV RT and exhibited detectable viral titers.  With the exception of the L151F, K152A,
F155Y, C157A and H161A mutants, the RT activities of all mutants were statistically
different from the wild-type RT activity (P < 0.002).  Finally, the RT activity of the
K103S mutant could not be compared with the wild-type RT activity, because the
mutation apparently generated a defect in Gag processing and the processed capsid
protein could not be detected upon Western blotting analysis (data not shown).
Therefore, the RT activity of the K103S mutant could not be normalized to the wild-type
RT.  Finally, reductions in titers were less than decreases in RT activity, except for the
Q190M mutant, suggesting that other steps in reverse transcription were affected by these
mutations introduced at positions constituting the dNTP-binding site of MLV RT.
DISCUSSION
In this study, we compared the primary amino acid sequences a  well as the
crystal structures of MLV and HIV-1 RTs to identify residues of MLV RT that are likely
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to contact the dNTP substrate.  Our extensive mutational analysis of these residues in
MLV RT strongly suggests that these residues are critical for proper polymerase function
and viral replication.  The location and orientation of MLV RT residues D153, A154,
F155, and Q190 are essentially identical to those of HIV-1 RT residues D113, A114,
Y115, and Q151, respectively (Fig. 2A and 2C)(11, 17.  In addition, the distances
between the side chains of these residues as well as K103 are very similar to those of the
equivalent residues of HIV-1 RT. The majority of the distances do not vary by more than
3.0 Å.  However, some of the bond distances between the R110 residue of MLV RT and
the other residues constituting the dNTP-binding site are much greater than the analogous
bond distances in HIV-1 RT.  The R110 residue, with respect to the other five residues,
appears in some cases to be as much as 4.0 Å farther away and as much as 6.0 Å closer
(depending on which dNTP binding site residues were used to measure distances to
R110) in comparison to the homologous distances in HIV-1 RT.  It is possible that the
MLV RT fingers domain that contains the K103 and R110 undergoes a larger movement
upon binding the dNTP substrate.  In addition, their location may be slightly altered in
the MLV RT crystal structure, since it lacks the thumb, connection, and RNase H
domains of MLV RT.
Several mutants of residues constituting the dNTP-binding site of MLV RT show
statistically significant alterations in fidelity relative to the wild-type RT.  These include
D153A, A154S, and F155W, characterized by 1.6-, 1.3-, and 2.8-fold increases in lacZ
inactivation, respectively (Table 1).  All three homologous residues in HIV-1 RT (D113,
A114, and Y115) have been observed to directly contact the incoming dTTP substrate
(18) and mutations in at least the A114 and Y115 residues have been implicated in
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alterations of the affinity for the dNTP substrate (32-34).  Interestingly, coordination of
the triphosphate moiety of the dTTP substrate by the D113 and A114 residues of HIV-1
RT is believed to be mediated by the main chain amino (NH) groups of these residues
and therefore, the side chains may not have a direct effect on dNTP binding (18).  This
lack of possible side chain involvement might account for the increased tolerability to
substitutions, at least at position D153 in MLV RT (equivalent to D113 in HIV-1 RT).
However, there appears to be a limit on the side chain size that can be accommodated in
this particular location due to the flexibility of the MLV RT dNTP binding pocket.  For
example, substitutions with amino acids containing large side chains (D153F and D153R)
displayed drastic reductions in titers (> 10,000–fold) and RT activities (30- to 50-fold).
In comparison, amino acids with smaller side chains (D153A, D153C, D153Q, and
D153S) were more readily accepted with slightly less severe effects on viral replication
and RT activity relative to the wild-type RT (Table 1).  On the other hand, the change in
fidelity displayed by D153A may be attributed to the small size of the side chain, which
could increase the overall flexibility of the dNTP binding pocket and alter the
discriminatory ability of this particular RT.  One would expect a similar pattern with the
A154 mutants of MLV RT.  However, the majority of substitutions at this position had
substantial effects on viral replication and RT activity relative to the wild-type RT (Table
1).   Our data suggests that an amino acid with a side chain containing more than two
carbons might alter the active site in the polymerase by repositioning critical residues
important for catalysis, since only the A154S mutant seems to have detectable levels of
viral replication.
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Residue Y115 in HIV-1 RT (equivalent to F155 of MLV RT) has been observed
to directly interact with the base and ribose moiety of the incoming dTTP substrate (18).
Furthermore, in vitro studies have observed that several Y115 mutants of HIV-1 RT
displayed reductions in the affinity for the correct dNTP, slight changes in processivity as
well as for alterations in the frequency of misinsertions and mispair extensions when
compared to wild-type HIV-1 RT (16, 33, 34).  Therefore, alterations in fidelity exhibited
by the F155W mutant of MLV RT (Table 1) may also be attributed to decreases in
affinity for the correct dNTP, increases in affinity for incorrect dNTP, and/or alterations
in processivity as observed with the Y115W mutant of HIV-1 RT (33).  In addition, the
reduction of RT activity associated with the F155 mutants, including F155W (Table 4),
may be due to decrease in the affinity for substrate (dNTP) that may have drastically
impeded catalysis.  This was proposed for mutants containing substitutions at the
homologous position in HIV-1 RT (34).  Decreased RT activity may thus account for the
drastic reduction in viral titers exhibited by these particular mutants (Tables 1 and 4).  In
addition, the aromatic side chain of the MLV RT homolog (F155) was proposed and later
shown to play a role in the selection of dNTPs over rNTPs (10, 11).  Our results also
support the importance of a bulky side chain at this position because only the F155W and
F155Y mutants generated detectable virus titers (Table 1).  Recently, the F155V mutant
of MLV RT was observed to incorporate UTP (10).  Although the F155V mutant in our
study exhibited an 18-fold reduction in RT activity (similar to the A154S mutant,
characterized by detectable viral replication), the incorporation of rNTPs into the proviral
DNA in vivo may account for the reductions in titer greater than 10,000-fold (Table 4).
In addition, due to the proximity of amino acids 154 and 155 to each other, the slight
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decrease in fidelity exhibited by the A154S mutant relative to wild type may be attributed
to indirect effects exerted on the F155 residue by the alanine to serine substitution.
The other three residues in HIV-1 RT that come in direct contact with the
incoming dTTP substrate are residues K65, R72, and Q151 (18). In addition, several R72
and Q151 mutants of HIV-1 RT were characterized by drastic reductions in Kcat as well as
decreased processivity and nucleotidyltransferase activities (24, 39, 40).  Furthermore,
similar findings have been made with the R110 residue of MLV RT, which is equivalent
to the R72 residue in HIV-1 RT (7).  As expected, the majority of substitutions
introduced at the homologous positions in MLV RT (K103, R110, and Q190) were
characterized by defects in viral replication (Tables 1 and 4), in support of the critical
roles of these residues (7, 16, 27, 39-41).  A number of HIV-1 RT mutants, such as K65A
and Q151N, were previously observed to be more accurate than the wild-type HIV-1 RT
in vitro, despite their unaltered affinities toward the dNTP substrates (16).  Interestingly,
the Q190M mutant of MLV RT exhibited no substantial changes in fidelity, viral
replication, or RT activity (Tables 1 and 4), in agreement with previously published
results obtained with the equivalent Q151M mutant of HIV-1 RT (16).
In this study, several other positions in MLV RT that are in proximity to the
dNTP binding residues were mutated and the effects of these mutations on replication,
RT activity, and fidelity were assessed and compared with those of the wild-type MLV
RT (Tables 2 to 4).  The side chain of F156 in MLV RT (equivalent to F116 in HIV-1
RT) is believed to form a part of the pocket that accommodates the 3¢ OH of the dNTP
substrate (18).  In addition, analysis of MLV RT crystal structure suggests that the F156
side chain might also be important for correct positioning of the Q190 side chain so that it
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can properly contact the dNTP substrate (11).  Our results indicate that the size of the
side chain introduced at F156 can affect fidelity, viral replication, and RT activity (Tables
2 and 4).  Small side chains (F156I, F156Q, and F156V) exhibited no detectable levels of
viral titer, whereas mutants possessing larger side chains (F156L, F156M, F156W, and
F156Y) permitted viral replication (Table 2).  It is likely that substitutions with amino
acids possessing smaller side chains disrupt interactions between residues 156 and 190 in
MLV RT, leading to a defect in reverse transcription.  Side chains of intermediate sizes
(F156L and F156M) may preserve the F156 and Q190 interaction, but alter the local
geometry of the dNTP-binding site in a manner that affects the proper function of RT and
alters fidelity.
Finally, additional mutations were introduced in MLV RT at various positions
located near residues constituting the dNTP-binding site as well as the F156 residue
(residues 147 to 152 and 157 to 161).  As expected from previous analyses of the D110
position of HIV-1 RT, which is involved in the coordination of the metal cation, the
equivalent D150 residue of MLV RT was highly conserved and did not tolerate the D to
E or Q substitutions (Table 3) (11, 31, 32).  Substitutions of the V148 and L149 positions
also resulted in undetectable viral titers, perhaps because they indirectly affected the
metal coordination by D150.  It is interesting to note that the L151 residue, which is C-
terminal to D150, is more tolerant of substitutions, characterized by the L151F mutant
that exhibited a large decrease in fidelity (Table 3).
Although, only small alterations in fidelity (no greater than 3-fold) were observed
with the MLV RT mutants of this study in comparison to the wild-type RT, it is possible
that the large changes in a specific type of mutation may be altered to a greater extent.
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For instance, a large increase in the rate of a specific substitution (1 of the possible 12)
may nevertheless be characterized by less than a 3-fold increase in the overall mutation
rate.  In addition, an increase in the rate at which deletions occur may account for the
large drops in titers associated with many of the MLV RT mutants.  Therefore, it will be
of interest to see what type of mutations these various RTs generate in comparison to
wild type.  Finally, retroviral polymerases may be functioning at an optimum,
maximizing a number of properties of the RT such as polymerization, processivity, and
fidelity.  Therefore mutations introduced in RT may have drastic effects in activity as
well as fidelity. This may also account for the severe drops in viral titers associated with
a number of these MLV RT mutants.  Furthermore, this may explain in our study the
absence of any mutant possessing a large increase or decrease in the fidelity.
Nevertheless, a 3-fold change in the fidelity of these mutants is unlikely to have a large
impact on retroviral evolution since selective forces may play a more of an important role
as explained by a previously proposed model (8).
The results presented in this study provide insight into the mechanisms by which
the fidelity of MLV RT can be manifested through interactions between amino acids and
the dNTP substrate.  Based on results from previous reports as well as sequence
comparison and alignment of MLV RT and HIV-1 RT sequences, we believe that we
have mutated the residues constituting the dNTP-binding site of MLV RT.  As illustrated
in this study, many non-conservative substitutions had deleterious effects on RT activity
and viral replication due to the conserved nature of each of these amino acid positions.  In
contrast, conservative changes reflected properties similar to those of the wild-type RT,
especially in the case of fidelity.  Therefore, future studies should probably involve the
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residues in MLV RT that are in close proximity to those believed to contact the dNTP
substrate.  These types of changes will preserve the nature of conserved residues
contacting the substrate, yet allow for the positional effects associated with these
substitutions to alter the properties of RT such as catalytic activity, fidelity, and
processivity.  This approach might yield a better understanding of enzyme-substrate
interactions and how drug-resistance develops, which may aid in the design of new
antiviral drugs.
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TABLE 1.  Effects of mutations in dNTP-binding site residues of MLV RT on the
frequency of lacZ inactivation
MLV RT
genotype
No.
of
expts.
No. of mutant
colonies/
total coloniesa
Frequency
 of lacZ
inactivation
(mean % ±
SE)b
Relative
change in
inactivation
of lacZc
Relative
viral titerd
Wildtype 13 522/10,300 5.4 ± 0.23 1.0 1.0
Mutant
K103R 2 154/2,740 5.6 ± 0.35 No change 0.04
K103L
K103S
K103W
2
2
2
NCe
NC
NC
NC
NC
NC
NAf
NA
NA
< 0.0001
R110C
R110H
R110I
R110L
R110M
R110S
R110T
2
2
2
2
2
2
2
NC
NC
NC
NC
NC
NC
NC
NC
NC
NC
NC
NC
NC
NC
NA
NA
NA
NA
NA
NA
NA
< 0.0001
D153A 4 154/1,816 8.4 ± 0.62 1.6 0.0007
D153C 2 65/1,154 5.7 ± 0.23 No change 0.0007
D153Q 2 58/1,150 5.2 ± 0.15 No change 0.001
D153S 2 111/2,241 5.1 ± 0.15 No change 0.03
D153F
D153R
2
2
NC NC NA
NA
< 0.0001
A154S 2 208/2,963 7.0 ± 0.10 1.3 0.015
A154E
A154F
A154L
A154N
A154P
A154R
2
2
2
2
2
2
NC
NC
NC
NC
NC
NC
NC
NC
NC
NC
NC
NC
NA
NA
NA
NA
NA
NA
< 0.0001
F155W 2 27/182 15.1 ± 1.44 2.8 0.0004
F155Y 2 131/2,474 5.3 ± 0.55 No change 0.31
F155D
F155E
F155I
F155M
2
2
2
2
NC
NC
NC
NC
NC
NC
NC
NC
NA
NA
NA
NA
< 0.0001
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F155V 2 NC NC NA
Q190M 2 44/836 5.3 ± 0.40 No change 0.6
Q190E
Q190H
Q190N
2
2
2
NC
NC
NC
NC
NC
NC
NA
NA
NA
< 0.0001
a Number of mutant colonies that displayed a white colony phenotype and total number
of colonies that were observed in 2 to 13 independent experiments.
b The frequency of lacZ inactivation was calculated as follows:  (Number of mutant
colonies in each experiment ¸ by total number of colonies) ´ 100%.  The standard errors
were determined by using the Two-Sample T-Test.
c The relative change in the frequency at which the lacZ gen was inactivated was
calculated as follows: frequency of la Z inactivation observed with mutant MLV RT ¸ by
frequency of lacZ inactivation observed with the wild-type MLV RT.  Statistical analysis
using a Two-sample T-Test showed that the D153A, A154S, and F155W mutants of
MLV RT displayed mutant frequencies significantly higher than that for the wild-type
MLV RT (P < 0.03).  The mutant frequencies obtained with the K103R, D153C, D153Q,
D153S, F155Y, and Q190M mutants of MLV RT were not significantly different from
that of the wild-type MLV RT (P > 0.05).
d Virus titer for each experimental group was determined by serial dilutions and
infections.  The average virus titer obtained with the wild-type MLV RT for this set of
experiments was 9.8 x 104 CFU/ml.  The relative virus titer represents a ratio of the virus
titer of mutant MLV RT obtained in each experiment divided by the virus titer obtained
with the wild-type MLV RT in parallel experiments.
e NC, represents no colonies present after G418 selection, signifying reductions in viral
titers > 10,000-fold.
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f NA, represents not applicable because the relative change in the inactivation of the l cZ
gene could not be determined, due to the absence of colonies after G418 selection.
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TABLE 2.  Effects of F156 mutations in MLV RT on the frequency of lacZ inactivation
MLV RT
genotype
No.
of
expts.
No. of mutant
colonies/
total coloniesa
Frequency
 of lacZ
inactivation
(mean % ±
SE)b
Relative
change in
inactivation of
lacZc
Relative
viral titerd
Wild type 8 283/5,524 5.5 ± 0.24 1.0 1.0
Mutant
F156L 2 85/955 8.9 ± 0.20 1.6 0.006
F156M 1 20/208 9.6 ± 0.00 1.7 0.006
F156W 2 57/1,340 4.3 ± 0.15 0.8 0.016
F156Y 4 268/6,391 4.3 ± 0.27 0.8 0.046
F156I
F156Q
 F156V
2
2
2
NCe
NC
NC
NC
NC
NC
NAf
NA
NA
< 0.0001
a The number of mutant colonies that displayed a white colony phenotype and the total
number of colonies that were observed in 1 to 8 independent experiments.
b The frequency of lacZ inactivation was calculated according to Table 1.
c The relative change in the frequency at which the lacZ gen was inactivated was
calculated as described in Table 1.  Statistical analysis using a Two-Sample T-Test
showed that the F156L and F156M mutants of MLV RT displayed mutant frequencies
significantly higher than that for the wild-type MLV RT (P < 0.001).  The F156Y and
F156W mutants exhibited mutant frequencies less than and statistically different from that
of the wild-type MLV RT (P < 0.05).
d Virus titer for each experimental group was determined by serial dilutions and infections.
The average virus titer obtained with wild-type MLV RT in this set of experiments was
8.1 x 104 CFU/ml.  The relative virus titer represents a ratio of the virus titer of mutant
MLV RT obtained in each experiment divided by the virus titer obtained with the wild-
type MLV RT in parallel experiments.
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e NC, represents no colonies present after G418 selection, signifying reductions in viral
titers > 10,000-fold.
f NA, represents not applicable, since the relative change in the inactivation of the lacZ
gene could not be determined, due to the absence of colonies after G418 selection.
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TABLE 3.  Effects of mutations in residues proximal to residues of the dNTP-binding
site of MLV RT on the frequency of lacZ inactivation
MLV RT
genotype
No.
of
expts.
No. of mutant
colonies/
total coloniesa
Frequency of
lacZ
inactivation
(mean % ±
SE)b
Relative change
in inactivation
of lacZc
Relative
viral titerd
Wild type 6 271/5,220 5.3 ± 0.26 1.0 1.0
Mutant
T147A 2 66/969 6.8 ± 0.10 1.3 0.02
V148D 2 NCe NC NAf < 0.0001
L149W 2 NC NC NA < 0.0001
D150E 2 NC NC NA < 0.0001
L151F 2 413/3,304 12.5 ± 0.50 2.4 0.12
K152A 2 109/1,438 7.6 ± 0.65 1.4 0.71
C157A 2 69/1,031 6.8 ± 0.20 1.3 1.10
R159A 2 51/797 6.3 ± 0.35 No change 0.51
H161A 2 139/2,202 6.3 ± 0.20 1.2 0.45
a The number of mutant colonies that displayed a white colony phenotype and total
number of colonies that were observed in 2 to 6 independent experiments.
b The frequency of lacZ inactivation was calculated according to Table 1.
c The relative change in the frequency at which the lacZ gen was inactivated was
calculated as for in Table 1.  Statistical analysis using a Two-Sample T-Test showed that
the T147A, L151F, K152A, C157A, and H161A mutants of MLV RT displayed mutant
frequencies significantly higher than that of the wild-type MLV RT (P < 0.04).  The
mutant frequency obtained with the R159A mutant of MLV RT was not significantly
different from that of the wild-type MLV RT (P > 0.09).
d Virus titer for each experimental group was determined by serial dilutions and
infections.  The average virus titer obtained with the wild-type MLV RT in this set of
experiments was 3.6 x 104 CFU/ml.  The relative virus titer represents a ratio of the virus
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titer of mutant MLV RT obtained in each experiment divided by the virus titer obtained
with the wild-type MLV RT in parallel experiments.
e NC, represents no colonies present after G418 selection, signifying reductions in viral
titers > 10,000-fold.
f NA, represents not applicable, since the relative change in the inactivation of the lacZ
gene could not be determined, due to the absence of colonies after G418 selection.
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TABLE 4.  RT activities of dNTP-binding site mu ants of MLV RT.
MLV RT
genotype
Average RT activity as (%) of wild
typea
(mean of % ± SE)
Viral titer as a (%) of wild typeb
Wild type 100 100
T147A 15.4 ± 0.9 2.0
V148D 3.0 ± 0.9 < 0.01
L149W 1.0 ± 0.3 < 0.01
D150E 1.3 ± 0.4 < 0.01
L151F 86.7 ± 0.4 12.0
K152A 37.9 ± 15 71.0
K103L 0.9 ± 0.5 < 0.01
K103R 15.6 ± 4.5 4.0
K103W 0.5 ± 0.2 < 0.01
R110C 0.8 ± 0.6 < 0.01
R110H 0.9 ± 0.6 < 0.01
R110I 0.5 ± 0.1 < 0.01
R110L 0.2 ± 0.1 < 0.01
R110M 0.3 ± 0.0 < 0.01
R110S 0.3 ± 0.1 < 0.01
R110T 0.4 ± 0.1 < 0.01
D153A 6.7 ± 1.0 0.04
D153C 9.9 ± 2.8 0.07
D153F 2.4 ± 0.3 < 0.01
D153Q 8.0 ± 0.6 0.1
D153R 1.3 ± 0.7 < 0.01
D153S 23. ± 4.3 3.0
A154E 0.3 ± 0.1 < 0.01
A154F 0.2 ± 0.0 < 0.01
A154L 0.4 ± 0.0 < 0.01
A154N 0.2 ± 0.1 < 0.01
A154P 0.3 ± 0.1 < 0.01
A154R 0.4 ± 0.2 < 0.01
A154S 5.5 ± 0.9 2.0
F155D 0.2 ± 0.2 < 0.01
F155E 0.9 ± 0.1 < 0.01
F155I 4.9 ± 3.6 < 0.01
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F155M 2.0 ± 0.4 < 0.01
F155V 5.5 ± 2.6 < 0.01
F155W 8.0 ± 3.5 4.0
F155Y 161.4 ± 36.9 31.0
F156I 0.8 ± 0.4 < 0.01
F156L 2.4 ± 1.3 0.6
F156M 8.5 ± 3.1 0.6
F156Q 1.1 ± 0.5 < 0.01
F156V 1.5 ± 0.3 < 0.01
F156W 11.1 ± 0.9 1.6
F156Y 14.8 ± 1.2 3.0
C157A 56.1 ± 6.0 110
R159A 30.6 ± 6.5 50.0
H161A 43.6 ± 19.1 130.0
Q190E 1.0 ± 0.4 < 0.01
Q190H 0.3 ± 0.1 < 0.01
Q190M 51.6 ± 2.2 60.0
Q190N 0.5 ± 0.1 < 0.01
a Average RT activities using virion-associated RT.  The activities shown are relative to
the wild-type MLV RT (set to 100%) using the Poly (rA)-Oligo d (T) template-primer
complex.  The results represent an average of 2 to 3 experiments.  SE represents the
standard error of the mean.  RT activities of all mutants seem to be statistically different
from that of the wild-type MLV RT (P < 0.002), except for the L151F, K152A, F155Y,
C157A and H161A mutants (P > 0.05).
b Viral titers of mutants as a (%) of the wild-type titer (set at 100%).  Viral titers represent
the ratio of the virus titer generated from mutant MLV RT obtained in each experiment
divided by the virus titer generated from the wild-type MLV RT in parallel experiments
and multiplied by 100.
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FIG. 1.  Structures of MLV-based constructs and rapid in vivo assay to identify structural
determinants in MLV RT that are important for fidelity.  The ANGIE P encapsidating
cell line is a D17-based cell line expressing both the MLV-based vector pGA-1 and pSV-
A-MLV-env.  The pGA-1 vector, which contains long terminal repeats (LTRs) and all
cis-acting elements of MLV, transcribes the E. coli lacZ and neo genes from the LTR
promoter.  The internal ribosomal entry site (IRES) of encephalomyocarditis virus is used
to express neo.  pSV-A-MLV-env expresses the amphotropic MLV envelope from a
truncated MLV LTR (DLTR) and the SV40 promoter-enhancer.  (1) Transfection of the
wild-type or mutated MLV gag/pol construct pLGPS into the ANGIE P cell line allows
for expression of the MLV gag and pol from the DLTR.  Infectious viral particles are (2)
harvested and (3) used to infect D17 cells.  G418R infected colonies are (4) selected,
resistant clones are (5) stained with X-Gal, and (6) the frequency at which la Z is
inactivated is determined.
117
virus
1. Transfection
2. Harvest
3. Infect
pLGPS
DLTR gag                pol p
pSV40 DLTR A-MLV env
LTR LTRlacZ IRES neo
GA-1
pSV-A-MLV-env
ANGIE P Cell Line
4. Select G418R clones
5. Stain w/ X-Gal
6. Determine Frequency of
lacZ inactivation
D17 Cells
Experimental Protocol
118
FIG. 2.  The dNTP-binding sites of MLV and HIV-1 RTs.  (A) Primary sequence
homology of the MLV and HIV-1 RT dNTP-binding sites.  HIV-1 and MLV RTs were
aligned through their TVLD, LPQG, and YXDD amino acid motifs.  Residues of the
dNTP-binding site of MLV RT were determined by further alignment with residues
proposed to constitute the dNTP-binding site of HIV-1 RT.  Two dots represent residues
that are identical, whereas one dot represents conservative changes between the two RTs.
Bold lettering represents residues constituting the dNTP-binding sites in both HIV-1 and
MLV RTs.  (B) Structure of HIV-1 RT dNTP-binding site modified from Huang et al.
(16).  The restricted structure contains amino acid positions K65, R72, D113, A114,
Y115, and Q151 interacting with the dTTP substrate.  Italic lettering represents the
equivalent residues in MLV RT constituting the dNTP-binding site.  Components of the
dTTP substrate are denoted as B, base; R, ribose sugar; and P, phosphate.  Dashed lines
represent interactions between the amino acid residues of RT and the dTTP substrate; mc
represents main chain interactions between the substrate and the RT.  (C) Comparison of
secondary structures of MLV and HIV-1 RTs constituting the dNTP-binding sites.  The
backbone of HIV-1 RT (amino acid sequences 63 to 76, 106 to 121, and 148 to 154) was
superimposed on the homologous structure in MLV RT (amino acid sequences 101 to
114, 146 to 161, and 187 to 193).  HIV-1 RT is represented in gray; MLV RT, in black.
Side chains of residues creating the dNTP-binding sites of MLV and HIV-1 RTs are
illustrated as wire frames.
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ABSTRACT
The antiretroviral nucleoside analog 2¢,3¢-dideoxy-3¢-thiacytidine (3TC) is a
potent inhibitor of wild-type human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT).  A methionine-to-valine or methionine-to-isoleucine substitution
at residue 184 in the HIV-1 YMDD motif, which is located at the RT active site,
leads to a high level of resistance to 3TC.  We sought to determine whether 3TC can
inhibit the replication of wild-type murine leukemia virus (MLV) RT, which
contains V223 at the YVDD active site motif, and of the V223M, V223I, V223A, and
V223S mutant RTs.  Surprisingly, the wild-type and all four of the V223 mutants of
MLV RT were highly resistant to 3TC.  These results indicate that determinants
outside the YVDD motif of MLV RT confer a high level of resistance to 3TC.
Therefore, structural differences among similar RTs might result in widely
divergent sensitivities to antiretroviral nucleoside analogs.
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Currently, 14 antiviral drugs have been approved for clinical use to combat
human immunodeficiency virus type 1 (HIV-1) infections (11, 54).  When used in
combination, many of these drugs have been shown to prolong the life expectancy of
infected individuals and slow the progression of AIDS (12, 14, 20, 21, 40, 42).  Most of
these drugs, both nucleoside and nonnucleoside inhibitors, have been designed to target
reverse transcriptase (RT) (2, 10, 53).  One of the compounds used in combination
therapy is the nucleoside analog 2¢,3¢-dideoxy-3¢-thiacytidine (3TC) (4, 20, 21, 37, 51).
The triphosphate form of 3TC inhibits reverse transcription through chain termination of
DNA polymerization, a function carried out by RT, and therefore has been observed to be
a potent inhibitor of both HIV type 1 and type 2 replication (2, 9, 10).  In addition to the
clinical benefits (20, 21, 37, 46) associated with the use of this nucleoside analog, 3TC
exhibits low toxicity, even at millimolar concentrations (7, 9, 15, 36).
All of the drugs being used for therapy to combat HIV-1 infections eventually
result in drug-resistant mutants, thereby allowing for the progression of the disease.
Resistance to 3TC is no exception and is characterized by a mutation at the methionine
184 position of the Tyr-Met-Asp-Asp (YMDD) motif found in HIV-1 RT (5, 17, 31, 48,
55).  A YXDD motif, where X is a variable amino acid, is highly conserved among the
many viral RNA polymerases as well as RNA-dependent DNA polymerases (43).  For
example, Rous sarcoma virus RT contains the YMDD motif, the RTs of retroelements
such as 297 (Gypsy-like group) and Int 32 (Line-like group) contain both the YLDD and
YADD sequences, and the poliovirus RNA polymerase contains the YGDD motif (43).
Mutations in the YXDD motif abolish enzymatic activity and alter the processivity and
fidelity of RT (3, 6, 23, 27, 39).  The prevalent mutation in HIV-1 RT associated with
131
3TC resistance is the M184V substitution (17, 48, 55), which confers a level of resistance
1000 times greater than that displayed by the wild-type enzyme (17, 55).  It has been
observed that the M184I variant, which is resistant to 3TC but is less catalytically active,
is selected first after initiation of 3TC treatment (5, 6, 31, 55), and then is replaced by the
M184V variant after long-term treatment with 3TC.
Mutations in the motif analogous to the HIV-1 RT YMDD domain are also
correlated with resistance to 3TC in other retroviruses.  The YVDD, YIDD, and YTDD
motifs are selected during 3TC treatment of cells infected with simian immunodeficiency
virus (SIV) or feline immunodeficiency virus (FIV) (8, 49). In addition, the YVDD and
YIDD motifs arise during 3TC treatment of hepatitis B virus (HBV)-infected cells and
patients (1).  The selection for mutations in the YXDD motif in other retroviruses as well
as in HBV has suggested that this determinant is widely associated with 3TC sensitivity.
Other mutations in HIV-1 and FIV RTs have been implicated to confer dual
resistance to 3TC and other nucleoside analogs.  Specifically, the E89G and G333E
mutations in HIV-1 RT are correlated with dual resistance to 3TC and either
phosphonoformic acid or 3¢-azido-3¢-deoxythymidine (AZT), respectively, in tissue
culture (29, 45).  The K65R mutation in HIV-1 RT is associated with resistance to 3TC
and 2¢,3¢-dideoxycytidine (ddC) (19).  Finally, the P156S mutation in FIV RT appears to
confer resistance to both AZT and 3TC (50).
Although HIV-1 and MLV RTs share only ~25% amino acid sequence identity,
the two proteins are structurally similar (18).  Comparison of the finger and palm
domains in HIV-1 and MLV RT crystal structures reveals similar tertiary structures (18,
25, 34).  In addition, many of the sequence motifs present in HIV-1 RT, such as the
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YXDD domain, the dNTP-binding site, and the conserved Leu-Pro-Gln-Gly (LPQG)
motif, are also present in MLV RT.  Importantly, the antiretroviral nucleoside analogs
AZT, ddC, 2¢,3¢-dideoxyinosine (ddI), and 2¢,3¢-didehydro-3¢ deoxythimidine (d4T),
which inhibit HIV-1 RT, also inhibit MLV RT (52). Therefore, since wild-type MLV RT
contains the YVDD motif, it was expected and recently shown to be resistant to 3TC
(44).
Based on the similarities between the HIV-1 and MLV RTs, we hypothesized that
the YMDD mutant of MLV RT would be sensitive to 3TC and the YIDD mutant would
be resistant.  To test this hypothesis, we generated viruses containing wild-type MLV RT
as well as several mutants at position V223 within the YVDD motif and compared the
titers of these viruses in several different target cells in the presence or absence of 3TC.
MLV mutants, target cells, and the ANGIE P cell line.  The construction of the
V223A, V223I, V223M, and V223S mutants was described previously (23).  The mutants
were generated from the parent plasmid pLGPS (Fig. 1A), which expresses the MLV gag
and pol genes from a truncated MLV long terminal repeat (DLTR) promoter (41).
The targets of infection in this study included the murine fibroblast cell line NIH
3T3 and the human osteosarcoma cell line 143B (both obtained from the American Type
Culture Collection).  The ANGIE P cell line (Fig. 1B) is a D17-based (dog osteosarcoma)
cell line expressing the construct pSV-A-MLVenv (obtained from the NIH AIDS
Research and Reference Program) and pGA-1, an MLV-based retroviral vector (Fig. 1A)
(23, 38).  The expression construct pSV-A-MLVenv encodes the amphotropic MLV
envelope gene, whereas pGA-1 expresses the bacterial b-galactosidase gene (lacZ) from
the LTR promoter.  In addition, pGA-1 also contains the neomycin phosphotransferase
133
gene (neo), which is utilized as a selectable marker during infection.  All cells were
maintained in Dulbecco’s modified Eagle’s medium (ICN Biochemicals) supplemented
with penicillin (50 U/ml; Gibco), streptomycin (50 mg/ml; Gibco), and bovine calf serum
(6% for ANGIE P and 143B cells or 10% for NIH 3T3 cells; HyClone Laboratories).
Protocol for determining sensitivity of MLV RT to 3TC.  The approach used to
determine the sensitivity of MLV RT to 3TC is outlined in Fig. 1B.  Briefly, either wild-
type or mutated pLGPS along with pSVa3.6, a plasmid that confers resistance to ouabain
(30), were cotransfected into the ANGIE P cell line.  Transfections were carried out by
the previously described dimethyl sulfoxide-Polybrene method (28) and the transfected
cells were then selected for resistance to 10-7 M ouabain.
To determine the sensitivity of the MLV RTs to 3TC, we separately pooled and
expanded more than 500 ouabain-resistant colonies for the wild-type and V223 mutants.
For each pLGPS construct, 5 ´ 106 ouabain-resistant cells were plated on 100-mm-
diameter dishes and the medium was changed 24 h later.  Virus was harvested after
another 24 h and serially diluted.  In the presence of Polybrene (50 mg/ml), the virus was
used to infect either NIH 3T3 or 143B cells for 4 h.  The target cells were plated at a
density of 1-2 ´ 105 cells per 60-mm-diameter dish.  In experiments conducted in the
presence of the drug, the target cells were incubated with 10 mM 3TC 4 h prior to
infection, 4 h during infection, and 24 h post infection.  The 3TC concentration used in
this study was 15- to 4000-fold higher than the mean 50% inhibitory concentration [IC50],
ranging between 2.5 nM to 0.67 mM, which was previously shown to inhibit several
different strains of HIV-1 (9).  The infected cells were then subjected to selection with
G418, an analog of neomycin (600 mg/ml for 143B and D17 cells and 1.2 mg/ml for NIH
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3T3 cells) 24 h after infection.  The effect of 3TC treatment on MLV replication (wild-
type and V223 mutants) was determined by the number of drug-resistant colonies
obtained in the presence or absence of 3TC.
Comparison of viral titers in the presence or absence of 3TC.  Viral titers were
determined by quantitation of G418-resistant NIH 3T3 and 143B cells after infection (the
data are summarized in Table 1).  ANGIE P cells transfected with wild-type pLGPS or
the V223A, V223I, V223M, or V223S mutant were previously shown to produce
infectious viral particles, and target cells infected with these viruses were expected to
confer resistance to G418 (23).  Two to four independent infections of NIH 3T3 and
143B cells, in the absence or presence of 3TC, were performed with virus containing
either the wild-type pLGPS or one of the four V223 mutants.
Infection of NIH 3T3 cells with the wild-type virus harvested from a single pool
produced titers that ranged from 2.7 ´ 104 to 1.3 ´ 105 CFU/ml in the absence of 3TC.
Treatment of the target cells with 3TC had no significant effect on the titers of the wild-
type virus (82%, relative to the untreated control).  Similarly, infection of NIH 3T3 cells
with the V223M mutant produced titers that ranged from 1.6 ´ 102 to 9.2 ´ 104 CFU/ml
in the absence of 3TC after harvesting virus from two different virus-producing pools.
Treatment of the target cells with 3TC did not substantially affect the titers of the V223M
mutant virus (57%, relative to the untreated control) when compared to the inhibition of
the luciferase-expressing HIV-1-based vector pNLuc (Fig. 2C).  Only a 2-fold change
was observed in the titers in the absence or presence of 3TC, which is probably not
significant considering the inherent variation that occurs during infections (23).  W  also
assessed the sensitivity to 3TC of other V223 mutants (V223A, V223I, and V223S) in
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NIH 3T3 cells; the results were similar to those obtained with the wild-type and V223M
mutant viruses.  In summary, viral titers in the presence or absence of 3TC varied by only
2-fold, suggesting that 3TC did not significantly inhibit either the wild-type or V223
mutant RTs during infection of NIH 3T3 cells.
To determine whether the lack of inhibition to MLV replication with 3TC
treatment was specific to NIH 3T3 cells, we also tested infection of 143B cells and D17
cells.  Infection of 143B cells with virus containing either the wild-type or V223M
mutant RT produced results similar to those obtained with NIH 3T3 cells.  Virus obtained
from wild-type pLGPS produced viral titers that ranged from 3.4 ´ 102 to 1.9 ´ 103
CFU/ml in the absence of 3TC.  Treatment of the target cells with 3TC had no significant
effect on the titers of the wild-type virus (110%, relative to the untreated control).  In
addition, infection of 143B cells with virus containing the V223M mutant RT produced
viral titers ranging from 1.0 ´ 01 to 2.5 ´ 102 CFU/ml in the absence of 3TC and 0.5 ´
101 to 1.3 ´ 102 CFU/ml in the presence of 3TC (57%, relative to the untreated control).
Similar results were obtained with D17 cells (data not shown).
Activation of 3TC in target cells.  The results obtained with viruses generated
and harvested from the ANGIE P cells that had been transfected with either the wild-type
or V223 mutant constructs showed that all MLV RTs were resistant to 3TC (Table 1).
There are two possible explanations for these results.  First, structural differences
between MLV RT and HIV-1 RT might account for the resistance of MLV RT to 3TC.
Second, the uptake and/or phosphorylation of the drug by the target cells might be
inefficient.  To address these possibilities, we generated infectious HIV-1 particles and
used them to infect the various target cells as previously described (32, 33) (Fig. 2A and
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2B).  Briefly, 293T (human embryonic kidney) cells were cotransfected with pNLuc and
pSV-A-MLVenv.  Pseudotyped virus stocks were harvested and used to infect NIH 3T3,
HeLa, 143B, and D17 cells in the presence or absence of 10 mM 3TC.  The target cells
infected in the presence of drug were incubated with 3TC for 4 h prior to infection, 4 h
during infection, and 24 h postinfection.  Two days postinfection, the cells were lysed
and the amount of luciferase activity present in the lysates was measured with a
luminometer (Tropix) (Fig. 2B).
Infection of NIH 3T3, 143B, and HeLa cells with the pNLuc-derived virus was
decreased 20-fold by 3TC treatment (Fig. 2C).  The D17 cells exhibited a 4-fold decrease
in pNLuc expression relative to no 3TC treatment.  Thus, in the same cell lines in which
MLV infectivity was not significantly affected, HIV-1 infectivity was substantially
reduced.  These results indicate that the lack of an effect of 3TC on MLV infectivity was
not due to problems associated with the uptake, phosphorylation, or other mechanisms
that interfered with the inhibitory activity of the nucleoside analog in these target cells.
The less efficient inhibition of pNLuc expression in the D17 cells in comparison to the
other target cells (Fig. 2C) could have been caused by either reduced uptake or
phosphorylation of 3TC in D17 cells.  Alternatively, this cell line might actively export
the nucleoside analog, thus reducing its efficacy.  Regardless of the mechanism, HIV-1
infection of different cell types in vivo might display divergent susceptibilities to 3TC or
other RT inhibitors.  Thus, the data obtained with the D17 cell line might have
implications for drug therapy in HIV-1-infected patients.
Mechanism of 3TC resistance in MLV RT.  3TC resistance arises in both
retroviral (HIV-1, SIV, and FIV) and nonretroviral (HBV) polymerases with catalytic
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sites containing the YMDD motif (1, 8, 17, 31, 48, 49, 55).  This resistance usually
results from a substitution of methionine to threonine, isoleucine or valine.  Based on
these observations, we expected that the wild-type MLV RT containing the YVDD motif
would be resistant (44) and the V223M mutant would be sensitive to 3TC.  It was
therefore surprising that both the wild-type and the V223M mutant were highly resistant
to 3TC.
The mechanism by which the M184V mutant of HIV-1 RT confers resistance to
3TC is unclear.  The methionine-to-isoleucine substitution at position 184 in HIV-1 RT
results in a repositioning of the template-primer complex, and this rearrangement might
result in a misalignment of the 3TC triphosphate with the template, resulting in a
decrease in the turnover rate (47).  Molecular modeling of the wild-type and M184I
mutant of HIV-1 RT has also suggested that steric hindrance between the b-L-
oxathiolane ring of 3TC triphosphate and the b-branched amino acids (valine, isoleucine,
and threonine) at position 184 interferes with 3TC binding (47).  It s important to note
that the proposed steric hinderance model does not preclude 3TC binding to RT in a
mode that is unfavorable to its incorporation.  In this regard, Feng and Anderson (13)
reported that 3TC triphosphate binds to the M184V mutant with a much higher Kd value
(5.2 mM) relative to the wild type HIV-1 RT (0.24 mM).  Similarly, Wilson et al (56)
suggested that b-L-2¢,3¢-dideoxy-5-fluoro-3¢-thiacytidine , a nucleoside analog that is
structurally similar to 3TC, binds with a higher affinity to the wild type HIV-1 RT than
the M184V mutant.  However, Krebs and coworkers did not find a substantial difference
in the Kd values for 3TC binding to wild type and M184V mutants (35).  Recent
evidence indicates that the 3TC can bind to the M184V and M184I mutants of HIV-1 RT,
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which results in a conformational change in the enzyme that affects the nature of RNase
H cleavages (16).
The fact that both the YMDD and YVDD motifs are highly resistant to 3TC
strongly suggests that other structural determinants of MLV RT may interfere with the
nature of 3TC binding through steric hindrance.  The previous observation that MLV RT
is sensitive to ddC (52) suggests that the steric hindrance involves the b-L-oxathiolane
ring of 3TC.  In accordance with the relatively low (~25%) amino acid sequence identity
between the MLV and HIV-1 RTs, structural alterations at or near the active site not
related to the YVDD motif of MLV RT may lead to steric hindrance and prevent 3TC
binding (18).  A comparison of distances between residues of the YXDD motif and dNTP
binding pocket of HIV-1 and MLV RTs reveals substantial differences (18, 24).
Distances in MLV RT, specifically between the residues of the YVDD motif and K103,
which is equivalent to K65 of HIV-1 RT (22), are more than 2 angstroms longer when
compared to HIV-1 RT.  It should be noted that the K65 residue of HIV-1 RT is
associated with dual resistance to 3TC and ddC (19).  These and other structural
differences might contribute to the divergent sensitivities to 3TC.
Additionally, amino acid differences between the MLV and HIV-1 RTs around
the dNTP-binding pocket may also provide the steric hindrance needed to confer 3TC
resistance.  Specifically, the MLV RT possesses a phenylalanine at position 155, which is
equivalent to the tyrosine 115 in HIV-1 RT.  The Y115 of HIV-1 RT has been shown to
interact with the ribose ring of a dNTP substrate (25).  Therefore, substitutions of the
phenylalanine for the tyrosine in MLV RT dNTP binding site may alter the nature of 3TC
binding.
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It is also conceivable that the structural differences near the active site or dNTP
binding site between MLV and HIV-1 RTs, alter the affinity or nature of binding of 3TC
triphosphate relative to dCTP by a mechanism not involving steric hinderance.  The
nature of the structural differences that confer high-level resistance to 3TC despite the
presence of a YMDD motif appears to be unique to MLV RT, since several other
retroviral RTs as well as HBV polymerase display sensitivity to 3TC when the YMDD
motif is present (1, 8, 49).  Understanding the nature of the structural differences that lead
to 3TC resistance in MLV RT might provide insights into the general mechanisms by
which retroviral RTs acquire resistance to nucleotide analogs.
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TABLE 1.  The effect of 3TC treatment on MLV replication
Target
cells
MLV
RT a
Expt.
no.
-3TC titer
(CFU/ml) b
+ 3TC titer
(CFU/ml) c
+3TC
relative titer
(mean ± S. E.) d
NIH 3T3 WT 1 3.7 ´  104 2.6 ´  104 0.70
2 2.7 ´  104 1.5 ´  104 0.56
3 7.2 ´  104 9.2 ´  104 1.28
4 1.3 ´  105 9.5 ´  104 0.73
Avg 0.82 ± 0.16
V223M 1 2.9 ´  102 1.4 ´  102 0.48
2 1.6 ´  102 1.0 ´  102 0.63
3 9.2 ´  104 6.9 ´  104 0.75
4 2.4 ´  104 1.0 ´  104 0.42
Avg 0.57 ± 0.07
V223I 1 3.4 ´  104 2.5 ´  104 0.74
2 2.6 ´  104 3.3 ´  104 1.27
Avg 1.01 ± 0.27
V223A 1 1.3 ´  102 1.9 ´  102 1.46
2 2.1 ´  102 2.0 ´  102 0.95
Avg 1.21 ± 0.26
V223S 1 4.3 ´  104 4.3 ´  104 1.00
2 8.3 ´  103 1.2 ´  104 1.45
Avg 1.23 ± 0.23
143B WT 1 1.9 ´  103 1.4 ´  103 0.74
2 3.4 ´  102 5.8 ´  102 1.70
3 4.3 ´  102 3.5 ´  102 0.8
4 1.2 ´  103 1.3 ´  103 1.10
Avg 1.10 ± 0.23
V223M 1 2.5 ´  102 1.3 ´  102 0.52
2 2.0 ´  102 8.3 ´  101 0.42
3 1.3 ´  101 1.1 ´  101 0.85
4 1.0 ´  101 0.5 ´  101 0.50
Avg 0.57 ± 0.09
a The genotype of MLV virus generated from transfection of  pLGPS (wild-type or V223
mutants of MLV RT) into the ANGIE P encapsidating cell line.
b The titer obtained from infections in the absence of 3TC.  The virus titer for each
experimental group was determined by serial dilutions.  In experiments using NIH 3T3
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target cells, four independent infections were performed with virus containing the wild-
type or V223M mutant RT, whereas two independent infections were performed for the
V223A, V223I, and V223S RTs.  In experiments using 143B target cells, four
independent infections were performed with virus containing the wild-type or V223M
mutant RT.
c The titer obtained from infections in the presence of 3TC.  The virus titer for each
experimental group was determined by serial dilutions.  Four independent infections were
performed in the presence of 3TC (10 mM) as described in footnote b for virus containing
either the wild-type or V223M RT.  The 3TC treatment included incubation of the target
cells 4 h prior to infection, 4 h during infection, and 24 h postinfection.
d The +3TC relative titer was calculated as follows:  [titer obtained in the presence of
3TC] ¸  [titer obtained in the absence of 3TC].  The mean ± standard error (S.E.) was
determined by the Sigma Plot 5.0 program.
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FIG. 1.  Structures of MLV-based constructs and protocol used to determine sensitivity
to 3TC.  (A) Structures of the MLV-based vector pGA-1 and the gag-pol expression
construct pLGPS.  The pGA-1 vector contains both LTRs and all ci - cting elements of
MLV and transcribes the E. coli lacZ and neo from the LTR promoter.  The internal
ribosomal entry site (IRES) (26 of encephalomyocarditis virus is used to express neo.
The construct pLGPS expresses the MLV gag-pol gene from a truncated viral LTR.  (B)
Experimental protocol.  ANGIE P, a D17-based cell line expressing pGA-1 and a vector
carrying the amphotropic MLV env gene (pSV-A-MLVenv), was separately transfected
with either the wild-type (V223) or mutated (V223A, V223I, V223M, and V223S)
pLGPS constructs.  Virus from pools of these transfected ANGIE P cells was harvested
and used to infect target cells (NIH 3T3 or 143B cells) for 4 h in the presence or absence
of 3TC (10 mM).  The target cells were also treated with 3TC (10 mM) 4 h preinfection
and 24 h postinfection in the drug treatment groups.  (C) Measurement of virus titer.  The
percent change in the virus titers of the wild-type and V223M mutant was measured in
the absence or presence of 3TC (10 mM).  Two to four independent experiments were
performed for NIH 3T3 and 143B cells.  Virus titers observed in the absence of 3TC
treatment were defined as 100%.
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FIG. 2.  Structure of HIV-1-based constructs and activation of 3TC in NIH 3T3, HeLA,
143B, and D17 cell lines.  (A) Structure of the HIV-1-based luciferase-expression vector
pNLuc, which contains both LTRs, other cis-acting elements required for viral
replication, and the gag-pol gene of HIV-1.  pNLuc expresses the luciferase reporter gene
(luc) from the LTR promoter.  (B) Experimental protocol.  The vectors pNLuc and pSV-
A-MLVenv were cotransfected into 293T cells and pseudotyped virus was used to infect
various target cells (NIH 3T3, HeLA, 143B, and D17) for 4 h in the presence or absence
of 3TC (10 mM).  The target cells were also treated with 3TC (10 mM) 4 h preinfection
and 24 h postinfection in the drug treatment groups.  (C) Measurement of
chemiluminescence.  The percent of chemiluminescence was measured in the absence or
presence of 3TC (10 mM).  At least two independent experiments were performed for
NIH 3T3, HeLA, 143B, and D17 cells.  Chemiluminescence measurements in the
absence of 3TC treatment were defined as 100%.
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CHAPTER 5
Fidelity, Drug-Resistance, and the Evolution of Retroviruses
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Infections, latency and the steady state model.  The progression f human
immunodeficiency virus type 1 (HIV-1) infections involves three phases that includes the
acute phase (primary infection), then clinical latency, and eventually, the clinical disease
known as acquired immunodeficiency syndrome (AIDS) (18).  The primary infection (1-
8 weeks) is characterized by a burst of viral replication (106 to 109 particles/ ml of cell-
free plasma) and decreases in CD4+ T cells counts that never completely rebound (17, 21,
32).  This is not only indicative of HIV-1 infections, because similar results are observed
during the infection of macaque monkeys by simian immunodeficiency virus (SIV) (12).
The second phase, clinical latency (8-10 years), is not a time of viral inactivity
and similar characteristics again are observed with both HIV-1 and SIV infections.  This
clinical latency is characterized by steady decreases in CD4+ T cells as well as for the
continual and rapid replication of virus, which leads towards the progression of AIDS (2,
18, 62, 84).  It has recently been proposed that a dynamic balance (steady state) exists
between infection, cell death, cell replacement, and virus clearance which can be
observed only when the system is perturbed, such as in the case with antiviral drugs (19,
44).  It was calculated in this model that small changes in selective pressures have more
of a drastic affect on the evolution of the virus than large increases in mutation rates.
Therefore, it is believed that the high replication and mutation (to a lesser extent) rates of
HIV-1 provide genetic variation, but selective forces drive the viral population’s overall
evolution.  Nevertheless, it is important to investigate the mechanisms that govern
fidelity, for without the initial variation that’s generated, there would inevitably be no
evolutionary potential present.  Finally, the fidelity of the viral encoded polymerase
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identified as reverse transcriptase (RT) may be one of the major contributors of this
generated variability observed in retroviral populations (9, 81).
Mutations and mutation rates of RTs.  The in vivo mutation rates of several
retroviruses have been measured to be ~ 1.0 × 10-5 /bp/replication cycle and the spectrum
of mutations occurring during a single cycle of replication were also determined (68-71,
78-80).  The types of mutations included substitutions, frameshifts, deletions, deletions
with insertions, duplications, and hypermutations.  It has been proposed that these
mutations could arise by three different mechanisms involving misincorporations,
dislocation mutagenesis, or template switching events. (46, 47, 64, 79-81, 106).
Substitutions are usually generated through the misincorporation of an incorrect
nucleotide whereas frameshifts and G to A hypermutations occur by dislocation
mutagenesis.  Simple deletions, deletions with insertions, duplications, and complex
hypermutations may arise by template switching events.  In conclusion, reassortment of
these various mutations can occur through both homologous and nonhomologous
recombination (47, 64, 106).
Mechanisms of fidelity.  The mechanisms by which fidelity is manifested by
polymerases are not completely known.  It has been hypothesized that DNA polymerases
may exploit a number of mechanisms to ensure accurate DNA synthesis.  At a basic
level, the initial discriminatory ability of polymerases may involve free energy
differences between the correct and incorrect base pairs, increasing fidelity by 5- to 150-
fold (65).  Furthermore, these differences in free energy could be magnified by the
exclusion of water from the active site, providing additional accuracy during DNA
synthesis (83).  These two features alone may account for the high degree of precision
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exhibited by these enzymes in copying DNA.  Beyond the initial screening of correct
versus incorrect base pairs, the presence of a proofreading mechanism designated as the
3´ to 5´ exonuclease activity, may enhance fidelity through the removal of an
incorporated mispaired nucleotide (27, 54).  Finally, the highly processive nature
observed in several DNA polymerase complexes involving interactions with additional
accessory proteins, may also affect the ability of these enzymes to copy DNA correctly
(57).  Collectively, these factors may contribute to the highly accurate synthesis of DNA
observed in nature and modifications in any one of these mechanisms may result in
altered fidelity (38, 59).
Murine leukemia virus (MLV) RT active site.  Comparison of several DNA
polymerase crystal structures including MLV and HIV-1 RTs, have revealed a conserved
tertiary organization between these various distinctly divergent DNA polymerases (5, 6,
27, 30, 37, 45, 48, 54, 56, 82, 91, 92).  Their similar structures are indicative of a right
hand with fingers, palm, and thumb, which may imply that all nucleotidyl transferases
employ similar mechanisms during the polymerization of DNA, despite their divergent
evolution.  Our investigation, in accordance with previous observations, revealed the
presence of a number of primary structures highly conserved between MLV and HIV-1
RTs (37, 45, 85).  These include the Thr-Val-Leu-Asp (TVLD), Asp-Ala-Tyr/Phe-Phe
(DAXF), Leu-Pro-Gln-Gly (LPQG), and the Tyr-X-Asp-Asp (YXDD) amino acid motifs
(Chapters 2 and 3).  Analysis and comparison of crystal structures between these RTs,
specifically in and around the active sites, demonstrate a similarity in the locations and
orientations of several amino acid motifs (Fig. 1) (Chapter 3, Fig. 2) (37, 45).  Further
support is evidenced by a comparison of MLV and HIV-1 RT active sites with regard to
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distances measured between residues of the YXDD boxes and the dNTP-binding sites of
the two enzymes (Tables 1 and 2).  These lengths were determined by the RasMol
program and were calculated as an average bond distance from a number of
measurements taken between the various atoms of the side chain pairs inspected.  The
majority of the lengths were within 3 Å (length of hydrogen bond) indicating that, indeed,
the active sites of these two RTs (MLV and HIV-1) were alike.  Similar results were
obtained when analyzing the distances between residues constituting the dNTP-binding
site of both MLV and HIV-1 RTs (Table 3 and 4).  Collectively, this distance data as well
as the mutational analysis of amino acids within the active site of MLV RT (Chapters 2
and 3) in accordance with crystal structure results, may allow for a more precise
comparison and understanding of the two polymerases (37, 45, 48, 49, 56).  These results
in turn may provide insight into the common mechanisms employed by all polymerases
such as those governing catalysis, processivity, and fidelity.
Although biochemical and structural data characterizing these MLV RT amino
acid motifs have been previously reported by a number of studies, our biochemical data
presents additional evidence, of the importance of these residues for proper enzyme
function.  (Chapters 2 and 3) (4, 16, 34, 37, 53, 100).  This importance is revealed in
alterations in fidelity as well as reductions in both viral titers and RT activities as
demonstrated by the V223 (YVDD motif) and the RNase H domain mutants of MLV RT
(Chapter 2, Table 1 and Fig. 3).  Similar findings were detected in our extensive
mutational analysis of residues constituting the dNTP-binding site of MLV RT (Chapter
3, Tables 1-4).  Our results also provide additional evidence that the MLV RT residues
that we mutated are also present in HIV-1 RT, suggesting that different RTs (~ 25%
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amino acid homology) more than likely utilize similar mechanisms during DNA
synthesis.  This is displayed by the comparable changes in fidelity and reductions in RT
activities which are observed in both MLV and HIV-1 RTs (Chapter 2 and 3) (10, 28, 61,
66, 104).  For example, the YVDD motif in HIV-1 RT (M184V mutant) has been
associated with a 2-fold increase in overall fidelity when compared to wild type (YMDD)
(28).  As expected, the presence of the YMDD motif in MLV RT (Chapter 2, Table 1)
exhibited a 1.8-fold decrease in fidelity relative to the wild-type RT containing the
YVDD motif.  In addition, several of our V223 and dNTP-binding site mutants displayed
similar RT activities as observed with HIV-1 RT (Chapter 2, Fig. 3) (10, 61).
Viral replication and RT activities.  Although extensive mutational analysis has
been performed on HIV-1 RT and to a lesser degree on MLV RT, the majority of these
studies have been carried out in vitro (7, 10, 14, 16, 41, 53, 61, 77, 99, 105).  A
comparison of viral titers and RT activities obtained by both the V223 and the dNTP-
binding site mutants in our study can be utilized to uncover possible correlations between
in vivo and in vitro results.  Generally, the reductions in viral titers of our MLV RT
mutants were greater than the decreases in RT activities, suggesting that additional steps
during reverse transcription were affected (Chapter 2, Fig. 2 and Chapter 3, Table 4).
This is not unusual since in vivo, RT is required to polymerize DNA as well as perform
two obligatory jumps.
We demonstrated that the V223 position of the highly conserved YVDD motif is
necessary for proper polymerase function of MLV RT, which may indirectly affect viral
replication (Chapter 2).  In the case of the V223A, V223M, and V223S mutants of MLV
RT and to a lesser extent the V223I mutant, a distinct correlation between reduction in
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titers and RT activities was evident (Chapter 2, Fig. 2).  For example, the V223A and
V223S mutants of MLV RT exhibited RT activities of ~5% and viral titers of ~2% in
comparison to the wild-type RT, indicating that the reductions in titer were attributed to
decreases in RT activities (Chapter 2, Table 1 and Fig. 2).  Similar results, but not as
pronounced, were observed by the remaining V223 mutants (V223I and V223M).  This is
also in agreement with the comparable mutants (M184 position) of the YMDD box in
HIV-1 RT (10, 105).
Results obtained from our RNase H mutants imply that this MLV RT domain may
play a crucial role during reverse transcription in vivo, but its influence on this process is
not attributed to alterations in the ability of MLV RT to synthesize DNA.  In contrast to
the V223 mutants of MLV RT, the RNase H domain mutants possessed RT activities
comparable to the wild-type enzyme with significant reductions in viral titers ranging
between 2.5- to 4.8-fold when compared to the wild-type RT (Chapter 2, Table 2 and Fig.
2). This was expected since the mutations were not part of the polymerase active site.
This is in accordance with previously published data, which shows that mutations in the
RNase H domain of MLV RT may affect processivity as well as viral replication (7, 8,
36, 100).  Therefore, it is likely that an alteration in processivity by these RNase H
mutants may account for the reductions in titers.  It is possible that these mutants may not
be able to complete reverse transcription efficiently, which would result in a lower
number of proviruses being generated.
Surprisingly, many of our dNTP-binding site mutants in general exhibited greater
decreases in RT activities in comparison to the homologous mutants at the equivalent
positions in HIV-1 RT (39, 41, 61, 66, 72, 89).  It is probable that these conflicting results
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may be attributed to differences between the two RTs despite their similarities (catalysis,
amino acid motifs, and overall tertiary structures).  The dNTP-binding site mutants also
failed to show a correlation between viral titers and RT activities as seen with the V223
mutants of MLV RT (Fig. 2) (Chapter 2, Fig. 2 and Chapter 3, Table 4).  However, our
data suggests that a certain degree of RT activity is necessary to complete reverse
transcription in vivo in the context of our assay (Chapter 3, Table 4).  The majority of
mutants displaying RT activities less than and equal to 3% exhibited reductions in viral
titers > 10,000-fold (no detectable viral titers) whereas mutants with RT activities of 5%
or greater produced detectable virus.  The exceptions were the F155I, F155V, and the
F156L mutants of MLV RT.  Interestingly, the phenotype of the F155V mutant (RT
activity 5.5% and no detectable viral titer) may be partly explained by its ability to
incorporate both dNTPs and ribonucleotides (rNTPs) (34).  Incorporation of rNTPs may
promote degradation of the preintegrated viral DNA or inactivate the provirus, thus
accounting for the > 10,000-fold reduction in viral titers (Chapter 3, Table 4).  This may
also be the case for the F155I mutant of MLV RT (34).
The ability of the F155V or F155I mutants to incorporate rNTPs could be
assessed by harvesting virus containing the mutant RTs, permeablizing the virus with
nonionic detergent, and measuring the incorporation of labeled UTP through the
utilization of an exogenous RT assay (Chapters 2 and 3).  The relative rates of rNTP
incorporation by these mutants can be determined through their comparison to wild-type
MLV RT.  In addition, increasing amounts of dNTPs in the presence of UTP could also
confirm that both of these mutant RTs readily utilize rNTPs.  If both substrates can be
incorporated into a nascent DNA chain, increasing amounts of a dNTP should compete
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with the labeled UTP, resulting in a decrease of radiolabeled product.  Detection of the
RNA or RNA/DNA hybrid generated by these mutants may also require inactivation of
the RNase H domain, which could recognize and potentially degrade these products.
As stated above, a majority of the dNTP-binding site mutants of MLV RT
exhibited severe reductions of viral titers (> 10,000-fold) in comparison to wild-type RT,
which correlate to decreases in RT activities (< 3%).  The decreases in RT activity could
be attributed to inefficient initiation of minus- or plus-strand synthesis, inefficient
elongation, or an inability of RT to perform the obligatory jumps.   It would be of interest
to determine where these blocks occur during reverse transcription.  This can be
accomplished by infecting target cells with mutant virus, isolating preintegrated viral
DNA, amplifying this DNA by PCR, and then resolving of the products by gel
electrophoresis.  Utilization of specific primer sets complementary to different regions of
the viral genome could allow us to dissect the nature of the block.  Also, the various
mutations generating detectable virus could be introduced in the context of a replication
competent virus and the growth kinetics of each mutant can be measured and compared
to wild-type MLV.  In conclusion, data obtained by this set of experiments may provide
additional information on the role that these particular amino acids of MLV RT play
during reverse transcription and viral replication.
Fidelity of MLV RT.  Mutational analysis of the V223 position, the RNase H
domain, and the dNTP-binding site of MLV RT indicate that a number of residues may
play a role in the overall fidelity of this particular polymerase (Chapters 2, 3, and 4).
However, the absence of large changes in fidelity (> 3-fold) observed with the mutants in
our studies suggests that although specific amino acids within MLV RT may significantly
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influence the accuracy of DNA synthesis, other factors may also play an important role in
fidelity.  One possibility is that specific residues or amino acid motifs may not be as
important as the overall structure of the protein.  Several studies have illustrated that
polymerases will undergo a number of conformational changes upon binding the
template-primer complex and then the incoming dNTP (5, 6, 27, 51, 58, 98).  These
conformational changes in turn may align the residues participating in catalysis with that
of the incoming dNTP, allowing for incorporation only when the correct base pair is
formed (92).  Consequently, several mutations in combination may be necessary to
observe alterations in fidelity greater than 3-fold.
Another possibility is that polymerases such as MLV RT have evolved in a
manner that optimizes several different properties, which work in concert with one
another to ensure proper enzyme function.  Therefore, it is possible that some residues of
the RT may play critical roles in several of these enzymatic properties.  In support of this,
a number of amino acids, specifically within the dNTP-binding site, have been implicated
with multiple functions in both MLV and HIV-1 RTs ( 6, 39, 52, 72, 73, 89, 90).
Therefore, dNTP-binding site mutations that alter fidelity may also modify the catalytic
and processive attributes of the enzyme, due to the proximity of these residues to the
active site (37, 48).  This may account for the absence of hypermutators (highly
inaccurate polymerases) in our extensive mutational analysis of MLV RT.  In order to
observe large changes in fidelity, we would probably also need to compensate for gross
changes in other properties of the polymerase, which may have detrimental effects on the
virus in the context of the in vivo assay.  This is quite likely why the majority of the
dNTP-binding site mutants of MLV RT exhibited severe reductions in viral titers and RT
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activities (Chapter 3, Table 4).  One therefore could speculate that RTs are at a threshold,
optimizing RT activity, processivity, and fidelity (or the amount of errors that could be
tolerated by the virus).  This optimization of RT properties by evolution may also explain
the absence of the hypomutator (highly accurate polymerase) phenotype in these present
studies.  If polymerases are optimizing several properties simultaneously, they must have
evolved to operate at the upper limits of their abilities.  It would therefore be difficult to
select or generate a more accurate polymerase with a substantial increase in fidelity
without affecting RT activity or processivity.  Hence, considerable reduction in fidelity
may inevitably have a drastic effect on polymerase activity.
Perhaps, this paradox could be circumvented through the use of replication
competent viruses harboring these various mutations and by allowing for the multiple
rounds of replication.  This may permit isolation of revertants with compensatory
mutations that retain their mutator phenotype, yet are characterized by increases in RT
activity.  After several rounds of replication, infected clones could be isolated and the
nature of the compensatory mutations could be determined by PCR analysis and
sequencing.  The mutant could be further characterized through the utilization of the
rapid in vivo assay (Chapter 2).  However, it is quite possible that no compensatory
mutations would be isolated and the mutant virus will revert to a virus with wild-type RT,
a phenotype that nature has selected already to operate at the optimum in regard to all
these polymerase properties.
Protein-substrate interactions and flexibility of the dNTP-binding site.  It has
been proposed that DNA polymerases can distinguish between correct and incorrect base
pairing by exploiting differences in the hydrogen bonding, shape, and free energy
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changes associated with a specific base pair (correct versus incorrect) (27, 54, 65, 75).
The ability to exploit these differences could be attributed to the flexibility of the
polymerase active site and/or to the specific interactions between the protein and its
substrates.  Therefore, mutations introduced within the active site of the polymerase
could change the flexibility of this pocket or the affinity of the polymerase for its
substrates, which could lead to alterations in the accuracy of DNA synthesis as observed
with HIV-1 RT (41).  These changes in turn would exaggerate or diminish the differences
(hydrogen bonding, shape, and free energy) between correct and incorrect base pairs
leading to an enzyme, which is more or less accurate.
Flexibility of the active site may encompass the dNTP-binding site and the
adjacent area of the protein that interacts with the template-primer complex (specifically
the base pair at the N position).  It has also been proposed that a correctly formed
Watson-Crick base pair will lie in an identical position in the minor groove of the DNA
with a distinctive shape and interact with several conserved residues of the polymerase
(27, 54, 75).  These protein-substrate interactions at least in the T7 DNA polymerase (and
possibly in the DNA polymerase of Bacillus stearothermophilus) involve hydrogen
bonding between R429 and the N3 of the primer 3´-terminus base and between Q615 and
the O2 of the complementary base (27, 54).  These protein-substrate interactions are
prevented in the event of a mispair and result in a possible misalignment of altered
substrate with residues of the active site.  Substitutions introduced in the site
accommodating the base pair could modify the local geometry of the area allowing for
the proper fit of a mismatch.  Mutations could also reposition or realign critical residues
with the substrate in a manner that promotes catalysis.  In addition, mutations at residues
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thought to directly contact either the dNTP or template-primer complex could alter the
affinity of the polymerase for its substrates.  Individually or cooperatively, these
modifications may influence the accuracy of DNA synthesis.
Our results provide evidence in support of both hypotheses.  We have
demonstrated that certain modifications introduced into the active site of MLV RT
(YVDD motif and the dNTP-binding site) can have statistically significant effects on the
fidelity of this particular polymerase (Chapter 2, Table 1 and Chapter 3, Tables 1, 2, and
3).  Furthermore, depending on the amino acid position and the nature of the substitution
(size) introduced into the active site of MLV RT, various degrees in the accuracy of the
polymerase were encountered signifying that some residues may have a greater impact on
fidelity than others.
Analysis of the MLV RT crystal structure reveals that the V223 side chain of the
YVDD motif is in close proximity to the 3´ OH group of the terminal nucleotide in the
primer and thus, may position the template-primer complex during polymerization (37,
56).  Our results support this hypothesis and we believe that the decreases in fidelity
exhibited by the V223A, V223M, and the V223S MLV RT mutants probably result from
the slippage of the template-primer complex with respect to the active site of the
polymerase (Chapter 2, Table 1).  This is likely, since the sequenced proviral DNAs from
two infected clones displaying the white colony phenotype contained +1 frameshift
mutations (Chapter 2, Fig. 3C).  An increase in the frequency with which these slippage
events occur could be influenced by decreases in the processive nature of the RT.  This is
in agreement with results obtained with mutants generated at the equivalent positions in
HIV-1 RT (10).  In accordance with previously published results, we propose that
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mutations in the dNTP-binding site could also affect protein-substrate interactions,
particularly those between the polymerase and the incoming dNTP.  For example, the
F155W showed a decrease in fidelity by 2.8 fold when compared to the wild-type RT
(Chapter 3, Table 1).  This is in agreement with the homologous mutant (Y115W) of
HIV-1 RT, which displayed increases in the frequency of misinsertions and mispair
extensions attributed to a decrease in affinity for the correct dNTP and an increase in
affinity for the incorrect dNTP  (72, 73).  It is conceivable that mutations at residues
D153 and A154 of MLV RT, which may directly contact the incoming dNTP, could also
have an influence on protein-substrate interactions.  However, it is noteworthy that the
interactions between these residues and the dNTP substrate involve the main chain and
therefore, substitutions in the side chains should still preserve the contacts (48).
We can speculate that a number of the MLV RT mutants may exhibit decreases in
fidelity through an increase in the flexibility of the dNTP-binding site (Chapter 3, Tables
1, 2, and 3).  This is evident for mutants of D153, A154, and F156 of MLV RT whose
various side chain sizes were observed to have an effect on fidelity.  For example, the
presence of alanine (a small side chain) at position 153 reduced fidelity of the polymerase
by 1.6-fold whereas a cysteine, glutamine, or serine had no effect in comparison to wild-
type RT.  Interestingly, it is probable that an arginine or phenylalanine (very large side
chains) at this position drastically constrained the dNTP pocket of the RT to the point that
all substrate dNTPs were excluded.  Therefore, no viral titers were detectable for these
mutants.  Similar effects were observed with mutants of residues A154 and F156, which
suggest that a side chain of ~2 carbon lengths or less (for A154) or > 3 carbon lengths
(for F156) may be important in exerting effects on fidelity (Chapter 3, Tables 1 and 2).
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This may also be the case for several other mutants of MLV RT that are in close
proximity to the dNTP-binding site, including T147A and K152A (Chapter 3, Table 3).
The results imply that by reducing side chain size, the flexibility of the dNTP-binding site
may increase, allowing for the accommodation of an incorrect base pair.  This in turn
could promote incorporation of the wrong nucleotide and result in inaccurate DNA
synthesis.  On a final note, the flexibility of the dNTP-binding site could also explain the
hypermutator or hypomutator phenotypes if they should ever be observed.  For example,
a more open binding pocket for the substrate may give rise to a less stringent RT that
indiscriminately incorporates mismatches such as with a hypermutator.  In contrast, a
decrease in this flexibility may constrain the binding pocket to the degree that only the
correct base pair can be accommodated creating a more accurate RT.
Fidelity and drug-resistance.  The similarities in MLV and HIV-1 RT structures
as well as sensitivity profiles to dideoxynucleoside analogs makes MLV RT an attractive
model system when it comes to dissecting the mechanisms by which drug-resistance
arises in HIV-1 RT (20, 37, 45, 85, 97, 99).  In contrast to these results, our study
provides compelling evidence suggesting that at least in the case of the nucleoside analog
2´, 3´-dideoxy-3´-thiacytidine (3TC), MLV RT may display the drug-resistant phenotype
through a different mechanism than that viewed with HIV-1 RT (88).  The YMDD motif
of several RTs including HIV-1 RT has been associated with sensitivity to 3TC, whereas
the YVDD, YIDD, and YTDD motifs have been shown to confer resistance to the drug
(15, 35, 93, 94, 102).  In addition, the selection of the YVDD motif in the distinctly
divergent polymerase of hepatitis B virus during 3TC treatment suggests that the
development and the manifestation of resistance to this particular nucleoside analog may
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involve a universal mechanism (1, 13, 20, 31, 99).  Surprisingly, several MLV RT
mutants containing the YMDD, YADD, as well as the YSDD motifs were all
characterized with resistance to 3TC, in contrast to HIV-1 RT (Chapter 4, Table 1 and
Fig. 2).
The administration of antiviral drugs in the course of an HIV-1 infection results in
the selection of drug-resistant mutants (19, 99).  From a different perspective, these drug-
resistant mutants that arise can be considered more accurate on the premise that they can
distinguish between the normal substrate (dNTP) and the inhibitor, thus preventing the
incorporation of the drug (39, 60, 102).  Although, this inability to incorporate the
nucleoside analog is sometimes up to 1000 times higher than wild type, the increase in
fidelity is probably not mediated through the traditional manner since canonical Watson-
Crick base pairing is preserved.  For example, 3TC will base pair with a complementary
G in the template. The mechanism by which this type of fidelity (resistance) is attained
involves alterations in the local geometry of the dNTP-binding site and may be
manifested through steric hindrance.
Recently, the crystal structure of the M184I mutant of HIV-1 RT containing the
YIDD motif was resolved which revealed the nature by which resistance to 3TC arises
(88).  It was proposed that 3TC resistance entails steric hindrance between the
oxathiolane ring of 3TC and the b-branched side chain of the isoleucine at position 184.
Our results imply that structural determinants other than the V223 position of MLV RT
must account for this discrimination towards 3TC, which results in resistance.  This
natural propensity of MLV RT (wild type or V223 mutants) to exhibit resistance to 3TC
may be attributed to differences in their dNTP-binding sites of MLV and HIV-1 RTs.
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For instance, amino acid(s) present in MLV RT and absent in HIV-1 RT could exert
additional steric hindrance and therefore exclude the drug from the active site or reduce
binding of the nucleoside analog, explaining the decreased efficacy of 3TC on MLV RT.
It is also plausible that 3TC binding may involve additional residues besides the M184
position in HIV-1 RT which are absent in MLV RT and may consequently affect binding
of the drug.
 A sequence comparison of amino acids of the HIV-1, simian immunodeficiency
virus (SIV), and feline immunodeficiency virus (FIV) RTs indicated the presence of a
tyrosine at the conserved DAYF motif whereas MLV RT has a phenylalanine at the
equivalent position (DAFF).  Interestingly, the Y115 residue of HIV-1 RT has been
proposed to be important for selection of dNTPs over rNTPs and has also been associated
with drug resistance to Abacavir, a carbocyclic nucleoside analog (48, 101, 103).  A
similar role has been proposed for the MLV RT equivalent (F155), at least in the case
dNTP selectivity (37).  Therefore, infection of target cells with the F155Y mutant of
MLV RT (Chapter 3, Table 1) in the presence or absence of 3TC could reveal if indeed
this position is the additional determinant conferring 3TC resistance.
Both the E89G and L74V mutants of HIV-1 RT have been shown to exhibit
resistance to the 3TC and dideoxynucleoside analogs, respectively (86, 96).  Comparing
the amino acid sequences and the secondary structures of both MLV and HIV-1 RTs
revealed that MLV RT lacks the E89 residue and has a valine at the equivalent L74
position of HIV-1 RT.  Depending on sequence alignment, the homologous E89 residue
in MLV RT may be an aspartic acid or a histidine.  It is possible that any one of these
residues may partake in an important role during the binding of the inhibitor.  Since the
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glutamic acid and/or leucine side chains are absent in the equivalent positions in MLV
RT, it is possible that both the wild-type and V223 mutant MLV RTs may have a natural
propensity toward 3TC-resistance.  Therefore, mutating these homologous residues in
MLV RT with the YMDD box in the backbone may render the mutants sensitive to the
nucleoside analog, 3TC.  Alteration of the dNTP-binding site may change the flexibility
of this pocket and ultimately have effects on the sensitivity profile of MLV RT for the
drug.  Further analysis may offer insights into how resistance is acquired and aid in the
development of more potent antiviral drugs.
The role of structural and accessory proteins in fidelity.  A hypothetical model
of the HIV-1 replication complex during the initial stages of DNA synthesis illustrates
the interaction of RT with a number of viral proteins including capsid (CA), matrix
(MA), nucleocapsid (NC), integrase (IN), and the accessory protein, Vpr (67).  There is
compelling evidence showing that at least some of these proteins may be important for
the overall fidelity of the RT complex.  NC has previously been implicated with the
efficiency of strand transfer in vitro whereas a Vpr deficient mutant of HIV-1 was
observed to display a 4-fold increase in the in vivo mutation rate (69, 87). This model
also proposes the possible involvement of IN, MA, and CA as well as several cellular
proteins, which may contribute to fidelity of reverse transcription and whose roles are
unclear at this time.
The structure and components of the MLV RT replication complex are currently
unknown, but it may be similar to that of HIV-1.  It would be interesting to investigate
the role that other viral proteins, in conjunction with MLV RT, may play in regards to
fidelity.  Although MLV lacks accessory proteins like Vpr, several structural proteins of
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the virus including the MLV NC, CA, MA, or IN may exert an effect on fidelity.
Extensive mutational analysis of any of these viral proteins could provide information on
the characteristics of the in vivo RT complex and the effect that each particular protein
has on accurate DNA synthesis.  This can be accomplished by mutating either NC, CA,
MA, or IN genes in pLGPS, transfecting these mutated plasmids into the ANGIE P cells,
harvesting virus, and infecting target cells (Chapter 2).  Any changes in the frequency of
lacZ inactivation in comparison to the wild type virus would signify that this particular
viral protein was possibly part of the complex and important for fidelity.  One of the
disadvantages to this approach is that all of these proteins (NC, CA, MA, and IN) are
necessary for other functions during the retroviral life cycle.  Therefore, it is likely that
the majority of the mutations may have deleterious effects on viral replication,
integration, or assembly.  This could be avoided by making conservative changes in these
proteins.
Structural or accessory proteins may also affect the processivity of RT, which
inevitably could influence fidelity.  This may be characterized by increases or decreases
in the occurrence of deletions, deletions with insertions, duplications, or complex
hypermutations.  In order to achieve highly processive DNA synthesis, many DNA
polymerases may interact with additional proteins such as the multimeric protein ring
designated as the sliding clamp (seen with E. coli DNA polymerase) or thioredoxin (seen
with T7 DNA polymerase) (27, 57).  These protein clamps and thioredoxin have been
observed to encircle the template-primer complex and possibly prevent polymerase
dissociation from the DNA.  To date, no sliding clamp has been described for RT that
would increase the overall processivity of the polymerase.  However, growing evidence
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suggests that the protein aggregation (viral and cellular encoded proteins) of the in vivo
RT complex could all hypothetically contribute to the processive nature of RT (67).
One aspect of the processive nature of RT that could feasibly be determined is the
ability of RT to generate frameshift mutations.  A cell line similar to the ANGIE P cells
could be designed containing an inactivating mutation (-1 frameshift in a run of similar
nucleotides) in the lacZ expressed from a retroviral vector within these cells. We could
then screen a number of RT mutants that regenerate a functional reporter by determining
the frequency of blue colonies to total number of colonies.  A comparison of the mutants
to the wild-type RT would give the relative change in the frequency with which lacZ is
activated by a + frameshift.
In addition to cellular proteins that may alter fidelity directly through their
interaction with RT, there are also a number of host proteins, other than RNA polymerase
(see Chapter 1), that may affect the overall mutation rate of a given retrovirus.  For
instance, mutations introduced during plus-strand DNA synthesis of reverse transcription
will result in a mismatch that can be corrected by host DNA repair machinery.  The
effects on fidelity by repair machinery have not been determined, but nevertheless they
may significantly contribute to the overall accuracy with which DNA is synthesized.  In
addition, modification of viral RNA by the host cell’s double-stranded RNA adenosine
deaminase (dsRAD) can be another mechanism by which mutations arise (11, 40, 55).  It
has been observed that dsRAD deaminates adenosines to inosines, which leads to A-to-G
hypermutations.  Therefore, the fidelity of reverse transcription may be affected by a
number of proteins, both viral and cellular, in addition to RT.
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Evolution of retroviruses.  Retroviruses are arranged in seven genera making up
the Retroviridae family.  Members of these genera exhibit considerable genetic
variability, exemplified by the absence of any detectable homology between their
nucleotide sequences (18).  A substantial genetic divergence is also observed amongst the
various groups within the Retroviridae genera encompassing the lentiviruses.  However,
amino acid sequence analysis of several viral genes has allowed for the classification
(phylogenic trees) of all of these viruses and the data suggests that the majority of regions
within these retroviral genomes have all co-evolved (24-26).  In contrast, a different
pattern is observed when analyzing amino acid sequences of env among various
retroviruses.  This data predicts that this part of the viral genome may have evolved
through recombinational events shared between different viruses as observed with the
generation of the mammalian type D viruses (24, 25, 95).  Therefore, taxonomic
classification of these viruses (especially the lentiviruses) is important for providing
insights into the evolution of these viruses, which are a potential concern to human
health.  In addition, the overall significance of RT’s role in the generation of this genetic
variation is unknown, yet it is of interest to speculate how much of this variability is
attributed to the fidelity of this polymerase and how this in turn may affect the evolution
of the viral population.
Origin and evolution of primate lentiviruses.  It is hypothesized that primate
lentiviruses evolved from a common ancestor 600-1200 years ago which suggests a
phylogenetic relationship between human and monkey retroviruses possessing similar
genetic organizations (3, 29, 76).  It has been hypothesized that members of the lentivirus
genera radiated out from a common ancestor present in the Cercopithecus monkey
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species and the resultant viruses continued to evolve as a group in primates (18, 42, 50).
Analysis of genomic sequences has revealed five discrete groups of primate lentiviruses
including groups of human immunodeficiency virus (HIV) types 1 and 2 as well as
groups of simian immunodeficiency (SIV) (18).  It has been shown that HIV-1 can be
grouped with SIVcpz (SIV that infects chimpanzees) whereas HIV-2 possesses
similarities to SIVsmm (SIV that infects the sooty mangabey monkeys).  A number of
these viruses, such as SIVsmm and SIVagm (SIV that infects African green monkeys),
are both nonpathogenic in their respective hosts despite persistent life-long infections
(18).  Yet, cross-species transmission of SIVsmm into macaques (not the natural host)
results in an acquired pathogenicity that leads to an AIDS-like disease (22, 63).
Interestingly, HIV- 2 may have arisen by cross-species transmission of SIVsmm from
sooty mangabey monkeys into humans (23, 33). The two viruses have similar sequences
and inhabit overlapping regions in Africa (43, 74).
The story of HIV-1 is not as clear and can be explained by two hypotheses (23).
One hypothesis suggests that the virus has always been present for some time but it was
contained in isolated populations.  Recently, the world has become a smaller place in
light of urbanization as well as world travel and the virus can more easily spread.  If this
were the case, then you would expect that the virus would have had ample time to evolve
with host and should be less pathogenic.  An alternative hypothesis suggests that HIV-1
may have originated from another species such as chimpanzees due to its likeness to
SIVcpz.  This would explain HIV-1’s pathogenicity and high mortality as well as
increasing prevalence and it is quite possible that the virus is still evolving.
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In conclusion, due to the evolutionary potential of retroviruses, it is possible that
HIV-1 will transform into a novel human pathogen wreaking more havoc than it already
has caused.  Recently, hantavirus and ebola virus outbreaks have shown how a virus can
move quickly from one host to another with disastrous effects.  The possibility in HIV-1
is almost endless due to its high replicative capacity and mutation rates, in addition to the
millions of infected people.  With all of this in mind, inaccurate DNA synthesis by the
retroviral RT may therefore play a significant role in the generation of novel pathogens
similar to HIV type 1 and 2, but with additional pathogenic properties.
Point mutations in cis-acting elements could increase expression (transcription or
translation) of the retroviral genome, which would have an effect on the replicative
capacity of the virus.  For instance, augmentation in the replication of HIV-1 or 2 could
potentially reduce the length of clinical latency (increase replication, increase viral load).
This could involve changes in the viral promoter or internal ribosomal entry site.
Changes in a number of viral proteins could also have dramatic effects in the
pathogenicity of the virus.  For example, mutations in the envelope glycoprotein of HIV-
1 and 2 may generate a virus with an altered cellular tropism so that this pathogen could
infect a greater number of different cell types.  In addition, a hypothetical
recombinational event between HIV-1 and some other virus (influenza) could potentially
generate HIV-1 that is spread as an aerosol and infects through the respiratory tract.
Finally, HIV-1 or 2 could capture an oncogene creating a novel pathogen with the
pathogenicity of HIV-1 and possessing a transforming power, which can give rise to a
number of malignancies.  This is observed with many different retroviruses (18).  In l ght
of this evolutionary potential exhibited by retroviruses, the effective management of both
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HIV-1 and HIV-2 infections as well as any novel variants (with additional pathogenic
properties) arising from these viruses, will inevitably require the better understanding of
RT fidelity and how drug-resistance develops.
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TABLE 1.  Distance comparison of side chains between YXDD box and dNTP binding
site residues of HIV-1 and MLV RTs.
Y183b Y222c M184 V223 D185 D224 D186 D225
Ka 23.9d 26.3 20.1 24.0 18.8 21.0 20.6 23.1
R 20.7 20.3 17.7 17.8 12.8 15.4 18.2 18.0
D 12.9 15.2 8.7 10.6 4.3 6.5 5.4 6.0
D 19.2 19.6 15.5 13.4 8.6 9.7 14.7 13.8
A 13.2 13.9 10.3 7.00 4.7 4.5 9.8 9.2
Y/F 9.0 11.1 8.8 6.1 8.00 6.5 11.6 10.7
Q 14.2 15.0 12.3 10.6 8.9 11.2 14.1 13.2
a Residues constituting the dNTP-binding site of MLV and HIV-1 RTs.  For MLV RT,
the residues include K103, R110, D153, A154, F155, and Q190 whereas the HIV-1 RT
equivalents are K65, R72, D113, A114, Y115, and Q151, respectively.
b Non-shaded columns represent the residues of HIV-1 RT YMDD motif, which include
Y183, M184, D185, and D186 as observed in the HIV-1 RT structure [Hsiou, et al 1996].
c Shaded columns represent the residues of MLV RT YVDD motif, which include Y222,
V223, D224, D226 as observed in the MLV RT crystal structure [Georgiadis, et al 1995].
d Distances are represented in Angstroms.  Each distance is an average distance
calculated from a number of measurements taken between two side chains, one
constituting a residue of the dNTP-binding site and the other, of the YXDD motif of
either MLV or HIV-1 RTs.  Measurements were obtained from the RasMol program
using either the HIV-1 RT crystal structure [Hsiou, et al 1996] or the MLV RT crystal
structure [Georgiadis, et al 1995].
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TABLE 2.  Distance comparison of Ca-Ca bonds between YXDD box and dNTP
binding site residues of HIV-1 and MLV RTs.
Y183b Y222c M184 V223 D185 D224 D186 D225
Ka 26.0d 32.1 22.56 29.8 21.9 28.4 23.7 29.8
R 23.7 26.3 19.98 23.5 18.7 22.1 21.7 24.2
D 10.1 9.7 8.89 9.1 5.4 5.5 4.8 4.5
D 14.2 14.4 11.00 11.3 8.3 8.8 11.7 11.7
A 11.2 11.8 8.30 8.4 6.2 6.4 9.7 9.9
Y/F 12.5 13.1 9.36 9.4 8.7 8.8 12.5 11.2
Q 15.8 16.3 12.09 12.9 11.9 15.5 16.1 18.6
a Residues constituting the dNTP-binding site of MLV and HIV-1 RTs.  For MLV RT,
the residues include K103, R110, D153, A154, F155, and Q190 whereas the HIV-1 RT
equivalents are K65, R72, D113, A114, Y115, and Q151, respectively.
a Non-shaded columns represent the residues of HIV-1 RT YMDD motif, which include
Y183, M184, D185, D186 as observed in the HIV-1 RT structure [Hsiou, et al 1996].
b Shaded columns represent the residues of MLV RT YVDD motif, which include Y222,
V223, D224, D225 as observed in the MLV RT crystal structure [Georgiadis, et al 1995].
c Distances are represented in Angstroms.  Each distance is the measurement taken
between two Ca atoms, one from a residue constituting the dNTP-binding site and the
other from a residue from the YXDD box of either MLV or HIV-1 RTs.  Measurements
were obtained from the RasMol program using either the HIV-1 RT crystal structure
[Hsiou, et al 1996] or the MLV RT crystal structure [Georgiadis, et al 1995].
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TABLE 3.  Distance comparison of side chain distances between residues constituting the
dNTP-binding site of HIV-1 or MLV RTs.
Ka Kb R R D D A A Y F Q Q
K - - 14.0 8.3c 19.4 18.7 22.2 23.7 21.5 22.5 17.2 17.2
R - - - - 8.7 12.6 13.0 16.7 12.2 14.6 8.1 9.6
D - - - - - - 6.2 6.7 9.3 8.4 9.0 11.6
A - - - - - - - - 5.9 5.7 9.0 8.8
Y/F - - - - - - - - - - 6.0 5.4
Q - - - - - - - - - - - -
a Non-shaded columns represent the dNTP-binding site residues of HIV-1 RT, which
include K65, R72, D113, A114, Y115, and Q151 as observed in the HIV-1 RT structure
[Hsiou, et al 1996].
b Shaded columns represent the dNTP-binding site residues of MLV RT, which include
K103, R110, D153, A154, F155, and Q190 as observed in the MLV RT crystal structure
[Georgiadis, et al 1995].
c Distances are represented in Angstroms.  Each distance is an average distance
calculated from a number of measurements taken between two side chains of residues
constituting the dNTP-binding site of either MLV or HIV-1 RTs.  Measurements were
obtained from the RasMol program using either the HIV-1 RT crystal structure [Hsiou, et
al 1996] or the MLV RT crystal structure [Georgiadis, et al 1995].
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TABLE 4.  Distance comparison of the Ca-Ca bonds between residues constituting the
dNTP-binding sites of HIV-1 or MLV RTs.
Ka Kb R R D D A A Y F Q Q
K - - 9.3c 8.6 19.0 22.9 21.8 26.1 21.5 25.6 17.4 20.5
R - - - - 13.3 15.5 16.1 18.6 15.4 17.7 11.6 12.9
D - - - - - - 3.77 3.8 5.9 5.7 9.8 10.2
A - - - - - - - - 3.9 3.8 9.7 9.5
Y/F - - - - - - - - - - 6.8 7.2
Q - - - - - - - - - - - -
a Non-shaded columns represent the dNTP-binding site residues of HIV-1 RT, which
include K65, R72, D113, A114, Y115, and Q151 as observed in the HIV-1 RT structure
[Hsiou, et al 1996].
b Shaded columns represent the dNTP-binding site residues of MLV RT, which include
K103, R110, D153, A154, F155, and Q190 as observed in the MLV RT crystal structure
[Georgiadis, et al 1995].
c Distances are represented in Angstroms.  Each distance is the measurement taken
between the two Ca atoms of residues constituting the dNTP-binding site of either MLV
or HIV-1 RTs.  Measurements were obtained from the RasMol program using either the
HIV-1 RT crystal structure [Hsiou, et al 1996] or the MLV RT crystal structure
[Georgiadis, et al 1995].
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FIG. 1.  Comparison of the HIV-1 and MLV RT active sites.  The MLV RT [Georgiadis,
et al 1995] and HIV-1 RT [Hsiou, et al 1996] crystal structures were superimposed on
one another using the RasMol program.  HIV-1 RT active is represented as a ribbon
where as MLV RT active site is illustrated as sticks.  It each active site includes a portion
of the fingers, the highly conserved DAY/F, LPQG, and YXDD motifs, as well as the
primer grip.
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FIG. 2.  Comparison of RT activities and viral titers of dNTP-binding site mutants.  (A)
Reverse transcriptase activity using virion-associated RT.  The activities shown are
relative to the RT activity determined for the wild type MLV RT (set to 100%).  The
results represent an average of 2 to 3 experiments.  The error bars represent the standard
error of the mean and virus numbered as follows: 1; Wt, 2; K103R, 3; D153A, 4; D153C,
5; D153Q,  6; D153S,  7; A154S, 8; F155W, 9; F155Y, 10; Q190M. (B) Summary of
virus titers obtained relative to the wild type viral titer (set to 100%).  The results
represent an average of 2 to 13 experiments and the error bars represent the standard error
of the mean.  The % titer is in log scale.
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APPENDIX
Construction of MLV RT Mutants
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FIG. 1.  Construction of the V223A, M, and S mutants of MLV RT.  All three mutants
were generated individually through the utilization of the plasmid pLGPS (template),
either V223A, V223M, or V223S single-stranded DNA oligonucleotides (mutagenic
primers), and a 5´ to 3´ mutagenesis kit.  The plasmid pLGPS is an MLV gag-pol
expression construct and Dam- denotes that the plasmid DNA was non-methylated. In
addition, YVDD represents the wild-type YXDD motif of MLV RT containing the V223
position coded by pol in pLGPS.   To insure the absence of any undesired mutations
introduced during mutagenesis, the BspEI-SalI inserts containing the appropriate
mutations at position V223 (V223A, V223M, or V223S) were subcloned back into the
backbone of pLGPS, which was also digested with both enzymes.  Each individual
mutant was screened by sequencing the BspEI-SalI fragments of each mutated pLGPS
plasmids and the correct structure of these plasmids was confirmed by extensive
restriction mapping.
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FIG. 2.  Construction of the V223I mutant of MLV RT.  The V223I mutant was
generated through the utilization of the plasmid pLGPS (template), the V223I single-
stranded DNA oligonucleotide (mutagenic primer), and a 5´ to 3´ mutagenesis kit.  The
plasmid pLGPS is an MLV gag-pol expression construct and Dam- denotes that the
plasmid DNA was non-methylated.  In addition, YVDD represents the wild-type YXDD
motif of MLV RT containing the V223 position coded by pol in pLGPS.  To insure the
absence of any undesired mutations introduced during mutagenesis, the BspEI-SalI
inserts containing the appropriate mutation at position V223 (V223I) was subcloned back
into the backbone of pLGPS, which was also digested with both enzymes.  The V223I
mutant was screened by digestion of plasmid with ClaI, a new restriction site introduced
during mutagenesis.  The V223I mutation and the correct structure of the mutated
plasmid were confirmed by the sequencing of the BspEI-SalI fragment and through
extensive restriction mapping.
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FIG. 3.  Construction of the Q190E mutant of MLV RT.  The Q190E mutant was
generated through the utilization of the plasmid pLGPS (template), the Q190E single-
stranded DNA oligonucleotide (mutagenic primer), and a Chameleon mutagenesis kit by
Stratagene.  The plasmid pLGPS is an MLV gag-pol expression construct and Dam-
denotes that the plasmid DNA was non-methylated.  In addition, LPQG represents the
wild-type LPQG motif of MLV RT containing the Q190 position coded by pol in pLGPS
where as the LPEG contains the Q190E mutation.  To insure the absence of any
undesired mutations introduced during mutagenesis, the BclI-SalI insert containing the
appropriate mutation at position Q190 (Q190E) was subcloned back into the backbone of
pLGPS, which was also digested with both enzymes.  The Q190E mutant was screened
by digestion of plasmid with Bsu36I, a new restriction site introduced during
mutagenesis.  The Q190E mutation and the correct structure of the mutated plasmid were
confirmed by the sequencing of the BclI-SalI fragment and through extensive restriction
mapping.  In addition, a pRMBNB derivative of Q190E (named pESQ190E) was also
generated in the same manner described above with pRMBNB being utilized as the
template instead of pLGPS.
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FIG. 4.  Construction of the Q190H and N mutants of MLV RT.  The Q190H and N
mutants were generated through the utilization of the plasmid pESQ190E (template), the
Q190H or Q190N single-stranded DNA oligonucleotides (mutagenic primers), and a
Chameleon mutagenesis kit by Stratagene.  The plasmid pESQ109E (pRMBNB
derivative) is an MLV gag-pol expression construct and Dam- denotes that the plasmid
DNA was non-methylated.  In addition, LPEG represents a mutated LPQG motif found in
MLV RT containing the Q190E mutation in p l whereas the LPXG is a LPQG motif
containing either the Q190H or Q190N mutation.  To insure the absence of any undesired
mutations introduced during mutagenesis, the BclI-SalI insert containing the appropriate
mutation at position Q190 (Q190H or Q190N) was subcloned back into the backbone of
pRMBNB, which was also digested with both enzymes.  The Q190H and Q190N mutants
were screened by digestion of plasmid with Bsu36I, since one of these sites had been
destroyed during mutagenesis.  The Q190H and Q190N mutations and the correct
structure of the mutated plasmids were confirmed by the sequencing of the BclI-SalI
fragments and through extensive restriction mapping.
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FIG. 5.  Construction of the RMBNB derivative of pLGPS.  The pRMBNB derivative of
pLGPS was generated through the utilization of the plasmid pLGPS (template), two
single-stranded DNA oligonucleotides (mutagenic primers), and a 5´ to 3´ mutagenesis
kit.  pRMBNB is a derivative of pLGPS with the addition of three unique restriction sites
in pol (Bst1107I, NsiI, and BstBI) at nucleotide positions 3416, 3446, and 3496, which
are locate in and around the dNTP-binding site of MLV RT.  These unique restriction
sites were introduced into pLGPS by two rounds of mutagenesis.  During the first round,
the Bst1107I and BstBI sites were introduced and in the subsequent mutagenic reaction,
the NsiI site was introduced.  To insure the absence of any undesired mutations
introduced during mutagenesis, the BclI-BspEI insert containing the unique restriction
sites (Bst1107I, NsiI, and BstBI) were subcloned back into the backbone of pLGPS,
which was also digested with both enzymes.  Dam- denotes that the plasmid DNA was
non-methylated.  The new generated pRMBNB was screened by digestion with Bst1107I,
NsiI, and BstBI.  In addition, the unique restriction sites and the correct structure of the
mutated plasmid was confirmed by the sequencing of the BclI-BspEI fragment and
through extensive restriction mapping.
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FIG. 6.  Construction of dNTP-binding site mutants of MLV RT utilizing synthesized
double-stranded DNA oligonucleotides (dsDNA oligos) (Scheme I).  The dNTP-binding
site mutants of MLV RT generated by Scheme I involved replacing the Bst1107I-NsiI
fragment of pRMBNB with a synthesized dsDNA oligo.  These dsDNA oligos were
complementary to the Bst1107I-NsiI fragment except for the appropriate mutation
introduced in pol (specifically the dNTP-binding site of MLV RT).  An additional
mutation (silent) was present in these dsDNA oligos generating a new XbaI site utilized
for screening.  The plasmid pRMBNB was digested with Bst1107I and NsiI, the
backbone was isolated, and the appropriate dsDNA oligos were cloned into these sites.
Scheme I was employed to generate dNTP-binding site mutants of MLV RT for amino
acid positions 147-153.
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FIG. 7.  Construction of dNTP-binding site mutants of MLV RT utilizing synthesized
double-stranded DNA oligonucleotides (dsDNA oligos) (Scheme II).  The dNTP-binding
site mutants of MLV RT generated by Scheme II involved replacing the NsiI-BstBI
fragment of pRMBNB with a synthesized dsDNA oligo.  These dsDNA oligos were
complementary to the NsiI-BstBI fragment except for the appropriate mutation introduced
in pol (specifically the dNTP-binding site of MLV RT).  An additional mutation (silent)
was present in these dsDNA oligos generating a new SpeI site utilized for screening.  The
plasmid pRMBNB was digested with NsiI and BstBI, the backbone was isolated, and the
appropriate dsDNA oligos were cloned into these sites.  Scheme II was employed to
generate dNTP-binding site mutants of MLV RT for amino acid positions 156-161.
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FIG. 8.  Construction of dNTP-binding site mutants of MLV RT utilizing synthesized
double-stranded DNA oligonucleotides (dsDNA oligos) (Scheme III).  The dNTP-
binding site mutants of MLV RT generated by Scheme III involved replacing the
Bst1107I-BstBI fragment of pRMBNB with a synthesized dsDNA oligo.  These dsDNA
oligos were complementary to the Bst1107I-BstBI fragment except for the appropriate
mutation introduced in pol (specifically the dNTP-binding site of MLV RT).  Additional
mutations (silent) were present in these dsDNA oligos generating new XbaI a d Sp I
sites utilized for screening.  The plasmid pRMBNB was digested with Bst1107I and
BstBI, the backbone was isolated, and the appropriate dsDNA oligos were cloned into
these sites.  Scheme III was employed to generate dNTP-binding site mutants of MLV
RT for amino acid positions 154-155.
220
A-8 Construction of dNTP-Binding Site
Mutants Utilizing dsDNA Oligos
(Scheme III)
pRMBNB
8.7kb
Digest with
Bst1107I/BstBI
1.
Bst1107I
BstBI
Isolate pRMBNB
Backbone
2.
Insert dsDNA oligo
and cloned back
into pRMBNB
3.
Bst1107I/BstBI
insert with mutation
Bst1107I BstBI
Mutated
pRMBNB
8.7kb
221
FIG. 9.  Construction of dNTP-binding site mutants of MLV RT utilizing PCR-based
mutagenesis.  These mutants were generated individually through the utilization of either
plasmid pLGPS or pRMBNB (template) and two sets of primers, each set containing a
mutagenic primer with the appropriate mutation.  Fragments containing the appropriate
mutations were generated into two steps.  During the first step, both a 5´ and 3´ fragment
were generated, which overlapped at the codon being mutated (X = mutation).  Both
fragments were isolated, purified, annealed to one another and extended in both
directions.  Product was isolated, purified, digested with appropriate restriction enzymes,
and fragment was cloned back into either pLGPS or pRMBNB.  Mutations and correct
structure of mutated plasmids were confirmed by sequencing and extensive restriction
mapping.  This method was utilized in the generation of all K103 and R110 mutants as
well as the Q190M mutant.  Both the K103 and the R110 fragments for these mutants
generated during the PCR-based mutagenesis were used to replace the BclI-Bst1107I
fragment of pLGPS or pRMBNB.  The Q190M fragment for this mutant generated during
the PCR-based mutagenesis was used to replace the NsiI-SalI fragment of pLGPS or
pRMBNB.
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RETROVIRUSES    1997 HALVAS
TALK PRESENTATION
STRUCTURAL DETERMINANTS OF MURINE LEUKEMIA VIRUS (MLV) REVERSE
TRANSCRIPTASE (RT) IMPORTANT FOR FIDELITY.
Elias K. Halvas, Jenny S. Svarovskaia, Ronald A. Mudry, Jr., and Vinay K. Pathak, Department of
Biochemistry and Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26505
Retroviruses exhibit high mutation rates that may be attributed to RT.  Structural features of RTs that are
important for accuracy of DNA synthesis are currently unknown.  Potential structural determinants of RT
that may be important for fidelity include the YXDD box, the conserved LPQG sequence, the dNTP
binding site, the thumb domain, and the RNase H domain.
We have developed a rapid in vivo assay to identify structural determinants associated with fidelity of
MLV RT.  The assay employs a D17-based encapsidating cell line (ANGIE P) that expresses the MLV
envelope gene and an MLV-based retroviral vector.  The MLV-based vector encodes the b-gala tosidase
gene (lacZ) which serves as a reporter of mutations and the neomycin drug resistance gene.  The MLV gag-
pol construct expressing the RT can be mutated at sites thought to be important for fidelity; the ANGIE P
cells are transfected with the wildtype or mutated MLV gag-pol constructs, and virus produced is used to
infect D17 target cells. Drug resistant colonies formed after one cycle of replication are X-Gal stained and
the rate of inactivation of lacZ is determined. The relative change in fidelity can be assessed by comparing
mutant RTs with the wildtype RT.
We have mutated the second amino acid in the highly conserved YVDD box to generate V223M and
V223S mutants of MLV RT.  In addition, RNase H domain mutants S526A and R657S were created.
Utilization of wildtype RT in our assay resulted in inactivation of lacZ at a frequency of 5.2% per cycle.  In
comparison, the V223M and the V223S mutants inactivated lacZ at higher rates of 9.2% and 12.3% per
cycle, respectively.  The S526A and R657S RNase H mutants also inactivated lacZ at higher rates of 8.5%
and 7.2% per cycle, respectively.  These results demonstrate that we have developed a system to identify
structural determinants important for fidelity.  In addition, the second amino acid of the YVDD box and the
structure of the RNase H domain play a role in the accuracy of DNA synthesis.
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POSTER PRESENTATION
STRUCTURAL DETERMINANTS OF THE PUTATIVE dNTP-BINDING SITE IN
MURINE LEUKEMEIA VIRUS (MLV) REVERSE TRANSCRIPTASE IMPORTANT FOR
FIDELITY.
Elias K. Halvas, Jenny S. Svarovskaia, Erin White, Ronald A. Mudry, Jr., and Vinay K. Pathak,
Department of Biochemistry and Mary Babb Randolph Cancer Center, West Virginia University,
Morgantown, WV 26505
Retroviruses exhibit high mutation rates, primarily because retroviral RTs carry out error-prone
DNA synthesis.  In vitro studies have indicated that several structural determinants of RT are important for
fidelity, which include the YXDD box, Q190 of HIV-1 RT, the dNTP-binding site, the thumb domain, and
the RNase H domain.  However, the structural features of RTs that are important for the accuracy of DNA
synthesis during retroviral replication are currently unknown.
We have developed a rapid in vivo assay to identify structural determinants associated with
fidelity of MLV RT.  The assay employs a D17-based encapsidating cell line (ANGIE P) containing an
MLV-based vector encoding the lacZ gene, which serves as a reporter of mutations.  The MLV gag-pol
construct expressing RT was mutated at sites thought to be important for fidelity; the ANGIE P cells were
transfected with the wild-type or the mutated gag-pol constructs, and the virus produced was used to infect
D17 target cells.  Drug-resistant colonies formed after one cycle of replication were stained with X-Gal and
the rate of lacZ inactivation was determined. The relative change in fidelity was assessed by comparing
mutant RTs to the wild-type RT, which inactivated the lacZ gene at a frequency of 5.5% ± 0.3%.
To determine the importance of the putative dNTP-binding site to the accuracy of DNA synthesis,
amino acid positions 147-161 of the MLV RT were subjected to extensive mutational analysis.  Three of
the amino acids in this region of MLV RT (D153, A154, and F155) are homologous to amino acids D113,
A114, and Y115 of HIV-1 RT, which have been shown to contact the substrate dNTP.  In addition,
mutations were introduced at position Q190 (equivalent to Q151 of HIV-1 RT).
A total of 28 different mutants were generated and tested.  Fourteen of the mutants exhibited virus
titers that were at least 10,000-fold lower than the titer of the wild-type MLV, and their fidelity could not
be determined.  Four mutants did not exhibit a change in fidelity.  The remaining mutants generated mutant
frequencies that were 1.2- to 2.6-fold higher than the wild type.  The D153A mutant exhibited a very low
virus titer and a mutant frequency of 8.2%.  The F155 was mutated to D, E, I, M, V, W, and Y.  The
mutants F155D, F155E, F155I, F155M, and the F155V had undetectable viral titers and their effect on
fidelity could not be determined.  The F155W exhibited a very low viral titer and a mutant frequency of
14.8%.  The F155Y mutant exhibited a viral titer that was 31% to that of the wild type; the mutant did not
display a change in fidelity.  All three mutants with substitutions at the Q190 position had undetectable
viral titers.
The results indicate that the F155 position of MLV RT is highly conserved since most of the
substitutions severely reduced the viral titers.  These results also demonstrate that several amino acids of
the putative dNTP-binding site of MLV RT can affect the fidelity of DNA synthesis during retroviral
replication.
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Graduate Research Summary
(i) I have examined fidelity of murine leukemia virus (MLV) reverse transcriptase (RT) during in vivo
DNA synthesis and have identified structural determinants with in the polymerase that may be crucial in
this mechanism.  This was accomplished through the development of a rapid in vivo assay.  Utilizing this
rapid in vivo assay, I have examined the role that the V223 position of the MLV RT YVDD motif plays in
fidelity of DNA synthesis, viral replication, and RT activity.  I have observed through the utilization of the
rapid in vivo assay that substitutions at the V223 position of MLV RT are correlated with changes in
fidelity and reductions in both virus titers as well as polymerase activity.  These findings suggest that the
V223 position of MLV RT may exert effects that are important for fidelity of in vivo DNA synthesis during
reverse transcription.
(ii) I have also examined the role of several amino acid positions constituting the putative dNTP binding
site of MLV RT and the effects these amino acids exert on fidelity, virus titers, and RT activity.  I have
observed through extensive site-directed mutagenesis and the utilization of the rapid assay that several
positions in this pocket of MLV RT alter fidelity and severely affect viral replication as well as polymerase
activity.  These findings suggest a critical role for several of these residues in accurate in vivo DNA
synthesis during reverse transcription, viral replication, and RT activity.
(iii) I have examined the mechanism of 3TC drug-resistance in vivo associated with V223 position of MLV
RT.  As expected, I as well as others, have observed that the wild type MLV RT containing the YVDD
motif was resistant to 3TC.  In contrast to 3TC-resistance in HIV-1 RT, various mutants of the V223
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position (V223M, V223I, V223A, and V223S) were also resistant to 3TC. These findings suggest that
although MLV and HIV-1 RTs are similar, structural differences between the two may account for different
drug-sensitivity profiles.
Technician Research Summary
(i) I have examined diversities in the extracellular matrices (ECMs) associated with the cornea as well as
the surrounding limbial epithelium and stroma.   I have identified that the long variant of type XII collagen
is a component of both the corneal and limbal ECMs.  These findings suggest the long variant of type XII
collagen may contribute to differences in the basement membrane zones of the cornea and limbus.
TECHNICAL SKILLS
Biochemistry
· Harvesting antibodies from
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and purification by affinity
chromatography
· Western blot analysis and ELISA
· Chemiluminescence detection
· Exogenous reverse transcriptase
assays
· Slot blot analysis
· Lowery and Bio Rad protein assays
· FPLC
· X-Gal staining of mammalian cells
· Cell extract preparation
(Amplification of DNA and
detection of protein)
· Conformational Polymorphism Gel
Electrophoresis
Molecular Biology
· DNA cloning
· DNA sequencing (manual and automated)
· PCR
· Double stranded DNA oligo-based
mutagenesis
· PCR-based mutagenesis
· DNA and RNA extraction and purification
· Extraction of viral RNA
· Southern blot analysis
Cell Culture
· Maintenance of several cell lines
(D17, NIH3T3, 143B, and a hybridoma)
· DNA stable transfections
· Isolation of cell clones
· Infection of several cell types
· Concentration of virus
PROFESSIONAL AND LEADERSHIP SKILLS
· Responsible for the direction of summer assistants assigned to me.
· Manuscript writing for publication
· Conducted seminar presentations (Cold Spring Harbor Laboratory retrovirus meeting and Van Leere
meeting)
· Poster presentation (Cold Spring Harbor Laboratory retrovirus meeting)
· Various computer skills relating to my field (DNASIS and Ras Mol)
· Teaching experience (Problem based learning for medical and dental students)
· Instructed a medical technology laboratory for undergraduates
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